NEW PEPTIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT

Abstract: A compound of the formula or its pharmaceutically acceptable salt: where, in one example, R¹ is n-octanoyl, n is the integer O, R₂ is benzyl, R₃ is 1-carboxyethylamino, R₄ is hydrogen and R⁵ is hydrogen and processes for their preparation and also a pharmaceutically composition comprising, as an effective ingredient, the above compound in association with phar­ maceutically acceptable carriers.

Description: NEW PEPTIDE, PROCESS FOR ITS PREPARATION AND PEIARMACEUTICAL- COMPOSITION CONTAINING IT This invention relates to a new peptide. More particularly, this invention relates to a new peptide and the pharmaceutically acceptable salt thereof, which have pharmacological activities, to processes for preparation thereof and a pharmaceutical composition comprising the same and a method of use thereof. The inventors of this invention and other inventors had previously synthesized a lot of peptide compounds and a patent application covering the same was filed in many countries (e.g. European patent application No. 80104502.2). Thereafter, the inventors of this invention further continued to make an extensive synthetic study so that they have succeeded- in synthesizing new peptides, which are generically-disclosed but specifically not disclosed in the specification of said application and have protective efficacy in experimental infection and an antitumor activity. A new pep tide of this invention is represented by the following formula (I) EMI2.1 wherein R1is n-octanoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is n-octanoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is benzyl, R3 is 1-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is hydrogen, R3 is 1-carboxyethylamino, R4 is hydrogen, and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is benzyl, R3 is methoxy, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is stearoyl, n is an integer of O, R2 is benzyl, R3 is methoxy, R4 is methoxycarbonyl and R5 is hydrogen; or * is stearoyl, n is an integer of 0, R2 is hydrogen, R3 is methoxy, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is n-docosanoyl, n is an integer of 1, R2 is benzyl, R3 is l-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is n-docosanoyl, n is an integer of 1, Rz is benzyl, R3 is 1-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is n-docosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or M is n-docosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is n-tetracosanoyl, n is an integer of 1, R2 is benzyl, R3 is 1-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is n-tetracosanoyl, n is an integer of 1, R2 is benzyl, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is n-tetracosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is benzyl, R3 is methoxycarbonylmethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is benzyl, R3 is methoxycarbonylmethylamino, R4 is methoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is hydrogen, R3 is methoxycarbonylmethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and: R5 is t-butoxycarbonyl; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is heptanoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbony; or R1 is heptanoyl, n is an integer of 0, R2 is methyl, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is heptanoyl, n is an integer of 0, R2 is methyl, R3 is 1-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is octanoyl, n is an integer of O, R2 is methyl, R3 is 1-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbbnyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is benzyl, R3 is methoxycarbonylmethylamino, R4 is carboxy, and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is'an integer of 1 R2 is hydrogen, R3 is methoxycarbonylmethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 1-N-n-hexyl-2,3,4,5-O-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is benzyl, -R3 is carboxymethylamino, R4 is 3-benzyloxycarbonyl carbazoyl and -R5 is benzyloxycarbonyl; or R1 is 1-N-n-hexyl-2,3,4,5,-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carbazoyl and R5 is hydrogen; or R1 is l-N-n-hexyl-2,3,4,5-O-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is l-N-n-hexyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, 4 5 R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is methoxycarbonylmethylamino, 4 5 R is carboxy and R is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R is methyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 2,3; 4,6-diisopropylidene-L-2-ketogulonoyl, n is an integer of O, R2 is benzyl, R3 is 1-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R is 2-keto-L-gulonoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is 2-keto-L-gulonoyl, n is an integer of O, R2 is hydrogen, R3 is 1-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is 2,3; 4,6-diisopropylidene-2-keto-L-gulonoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is 2-keto-L-gulonoyl, n is an integer of O, RZ is benzyl, R3 is 1-carboxyethylamino, 4 5 R is carboxy and R is hydrogen; or R1 is 2-keto-L-gulonoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is stearoyl, n is an integer of 1, R2 is benzyl, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is stearoyl, n is an integer of 1, R2 is hydrogen, R3 is 1-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is hydrogen; or R1 is heptanoyl, n is an integer of 1, R2 is benzyl, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is heptanoyl, n is an integer of 1, R2 is hydrogen, R3 is 1-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is hydrogen; or R1 is 1-N-benzyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is 3-benzyloxycarbonyl carbazoyl and R5 is benzyloxycarbonyl; or R1 is 1-N-benzyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carbazoyl and S R is hydrogen; or R1 is 1-N-benzyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is l-N-benzyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 1-N-lauryl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is 3-benzyloxycarbonyl carbazoyl and S R is benzyloxycarbonyl; or R1 is 1-N-lauryl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carbazoyl and R5 is hydrogen; or Rl is 1-N-lauryl-2,3,4,5-O-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 1-N-lauryl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, 4 5 R4 is carboxy and R is hydrogen; or R1 is palmitoyl, n is an integer of 1, R2 is benzyl, R3 is l-carboxyethylamino, R4 is carboxy and R5 is benzyloxycarbonyl; or R1 is palmitoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, 4 S R is carboxy and R is hydrogen; or R1 is. triacontanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is triacontanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is heptanoyl, n is an integer of O, RZ is benzyl, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is benzyloxycarbonyl; or 9 is heptanoyl, n is an integer of O, R2 is hydrogen, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is hydrogen; or R1 is heptanoyl, n is an integer of 0, R2 is benzyl, R3 is l-carboxyethylamino, S R4 is ethoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is heptanoyl, n is an integer-of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is ethoxycarbonyl and R5 is hydrogen. A A pharmaceutically acceptable salt of the new peptide of the formula (I) may include a salt with an inorganic or organic base such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g. calcium salt, etc.), ammonium salt, organic amine salt (e.g. ethanolamine salt, triethylamine salt, dicyclohexylamine salt, etc.), or the like, and an acid addition salt with organic or inorganic acid such as methane sulfonate, hydrochloride, sulfate, nitrate, phosphate or the like. The new peptide (I) of this invention can be prepared by various methods which are explained in detail as follows (I) Pep tide bond formation : EMI10.1 EMI11.1 EMI12.1 EMI13.1 EMI14.1 EMI15.1 EMI16.1 EMI17.1 EMI18.1 glucaramoyl or 1-N-lauryl-2,3,4,5-0-tetraacetyl-Dglucaramoyl. EMI19.1 EMI20.1 wherein Rb1 is n-docosanoyl or n-tetracosanoyl, EMI20.2 EMI21.1 (IV) Elimination of protective groups : EMI21.2 wherein R1 is n-octanoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, 5 R4 is hydrogen and R is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is benzyl, R3 is methoxy, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is stearoyl, n is an integer of 0, -R2 is benzyl, R3 is methoxy, -R4 is methoxycarbonyl and R5 is hydrogen; or R1 is n-docosanoyl, n is an integer of 1, i2 is benzyl, R3 is l-methoxcarbonylethylamino, -R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or -I is n-docosanoyl, n is an integer of 1, R2 is benzyl, R3 is l-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; R1 is n-tetracosanoyl, n is an integer of 1, is is benzyl, R3 -is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is n-tetracosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is-hydrogen; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is benzyl, R3 is methoxycarbonylmethylamino, R4 is methoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is heptanoyl, n is an integer of 0, R2 is methyl, R3 is 1-methoxycarbonylethylamino, 4 5 R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is octanoyl, n is an integer of O, R2 is methyl, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1- is 2-hydroxypropionyl, n is an integer of 1, R2 is benzyl, R3 is methoxycarbonylmethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is 1-N-n-hexyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is benzyl, R3-is carboxymethylaminp, R4 is 3-benzyloxycarbonyl carbazoyl and R5 is benzyloxycarbonyl; or R1 is 1-N-n-hexyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n@ is an integer of 1, R2 is hydrogen, R3is carboxymethylamino, R4 is carbazoyl and R5 is hydrogen; or R1 is 1-N-n-hexyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2is methyl, R3 is carboxymethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is 2,3; 4,6-diisopropylidene-L-2-ketogulonoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is 2-keto-L-gulonoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is 2,3; 4,6-diisopropylidene-2-keto-L-gulonoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is 2-keto-L-gulonoyl, n- is an integer of 0, R2 is benzyl, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is stearoyl, n is an integer of 1, R2 is benzyl, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is heptanoyl, n is an integer of 1, R2 is benzyl, R3 is l-ethoxycarbonylethylamino, R4 is ethoxyzarbonyl and R5 is benzyloxycarbonyl; or R1 is 1-N-benzyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n -is an integer of 1, R2 is benzyl, R3 is carboxy inethylamino, R4 is 3-benzyloxycarbonylcarbazoyl and R5 is benzyloxycarbonyl; or R1 is 1-N-benzyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carbazoyl and R5 is hydrogen; or R1 is 1-N-benzyl-2,3,4,5-O-tetraacetyl-D-glucaramoyl, n3 is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino R4 is carboxy and R5 is hydrogen; or R1 is 1-N-lauryl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is 3-benzyloxycarbonyl carbazoyl and R5 is benzyloxycarbonyl; or R1 is 1-N-lauryl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carbazoyl and R5 is hydrogen; or R1 is 1-N-lauryl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is palmitoyl, n is an integer of 1, R2 is benzyl, R3 is l-carboxyethylamino, R4 is carboxy and RS is benzyloxycarbonyl; or R1 is triacontanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is t-butoxycartonyl; R1 is heptanoyl, n is an integer of 0, R2 is benzyl, R3 is 1-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is heptanoyl, n is an integer of 0, R2 is benzyl, R3 is l-carboxyethylamino, k4 is ethoxycarbonyl and R5 is benzyloxycarbonyl, EMI26.1 wherein R1 is n-octanoyl, n is an integer of 0, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is benzyl, R3 is methoxy, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is stearoyl, n is an integer of 0, R2 is hydrogen, R3 is methoxy, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is n-docosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is n-docosanoyl; n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is n-tetracosanoyl, n is an integer of 1, Rê is hydrogen, R is 1-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or RÚ is n-tetracosanoyl, n is an integer of 1, Rê is hydrogen, R is 1-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or RÚ is 2-acetoxypropionyl, n is an integer of 1, Rê is hydrogen, R is methoxycarbonylmethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or RÚ is heptanoyl, n is an integer of 0, Rê is methyl, R is 1-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or RÚ is octanoyl, n is an integer of 0, Rê is methyl, R is 1-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or Rê is 2-hydroxypropionyl, n is an integer of 1, Rê is hydrogen, R is methoxycarbonylmethylamino, R4 is carboxy and R5 is hydrogen; or RÚ is 2-hydroxypropionyl, n is an integer of 1, Rê is hydrogen, R is carboxymethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or RÚ is 1-N-n-hexyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, Rê is hydrogen, R is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or RÚ is 1-N-n-hexyl-D-glucaramoyl, n is an integer of 1, Rê is hydrogen, R is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 2-keto-L-gulonoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is 2-keto-L-gulonoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, 4 5 R4 is carboxy and R is hydrogen; or R1 is stearoyl, n is an integer of 1, R2 is hydrogen, R3 is l-ethoxycarbonylethylamino, 5 R4 is ethoxycarbonyl and R is hydrogen; or R1 is heptanoyl, n is an integer of 1, R2 is hydrogen, R3 is 1-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is hydrogen; or R1 is 1-N-benzyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is l-N-benzyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 1-N-lauryl-2,3,4,5-O-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, n3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is l-N-lauryl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is palmitoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, S R4 is carboxy and R is hydrogen; or R1 is triacontanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, S R is carboxy and R is hydrogen; or R1 is heptanoyl, n is an integer of O, R2 is hydrogen, R3 is l-ethoxycarbonylethylamino, 4 5 R4 is ethoxycarbonyl and R is hydrogen; or R1 is heptanoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is ethoxycarbonyl and R5 is hydrogen. (I) Peptide bond formation t(l) to (18)]: The reaction of this process can be conducted as follows. That is, in one case, as the first step, the carboxy group of each carboxy compound or its salt is usually activated in a conventional manner, for example, in the form of its acid halide, azide, acid anhydride or a mixed anhydride, activated ester, and the like, and is reacted with each amino compound to give the object compound, and in the other case each carboxy compound or its salt is reacted with each amino compound or its salt directly in the presence of a conventional condensing agent such as N,N-dicyclohexylcarbodiimide and the like. Among these activation methods, preferred activation method for the carboxy group of each carboxy compound into its activated fÏrm and preferred condensing agent as mentioned above are selected according to kind of :¯the carboxy protective group(s) of each carboxy compound and each amino compound and to the reaction conditions (e.g. the kinds of the reaction solvent, reaction temperature and so on). - ¯ This reaction is preferably carried out in a solvent such as methylene chloride, chloroform, tetrahydrofuran, dioxane, ethyl acetate, methanol, ethanol, water or the like under at -200C to at ambient temperature and the reaction in the presence of a condensing agent is usually carried out in an -anhydrous, but not critical conditions. (II) Acylation [(1) and (2)]: -The reaction of this process is conducted by reacting each starting compound or its salt with l-N-n-hexyl-2,3,4,S-O-tetraacetyl-D-glucaramic acid, 1-N-benzyl-2 , 3,4, 5-0-tetraacetyl-D-glucaramic acid, l-N-lauryl-2,3,4,5-O-tetraacetyl-D-glucaramic acid or triacontanoic acid, or their reactive derivatives. As such reactive derivatives, there may be exemplified an acid halide, an acid azide, an acid anhydride, an activated amide, an activated ester, etc. In the reaction, when a free acid is used as an acylating agent, the acylation may preferably be conducted in the presence of a conventional condensing agent. - The reaction is usually conducted in a solvent such as water, alcohol (e.g. methanol, ethanol, propanol, etc.), acetone, ethyl ether, dioxane, acetonitrile, ethyl acetate, methylene chloride or other conventional solvents, or a mixture thereof. The reaction may also be preferably conducted in the presence of a conventional organic or inorganic base. There is no limitation to this reaction temperature and this reaction may preferably be conducted within the range of cooling to ambient temperature. ( Methylation r (1) to (4)] The reaction of this process is conducted by reacting each starting compound with a methylating agent. As such a methylating agent, there may be exemplified a conventional one such as methanol or its reactive equivalent (e.g. halide, sulfate, aliphatic or aromatic sulfonate or the corresponding diazo compound, etc.) or the like. The reaction is usually conducted in a solvent such as tetrahydrofuran, chloroform or other conventional solvent, or a mixture thereof. The reaction is usually conducted within the range of cooling to ambient temperature. (IV) Elimination of protective groups This process relates to a method for preparing the compound (it) or its salt by subjecting the compound (Iat or its salt to an elimination reaction of amino and (or) carboxy protective group(s). (IV-1), Elimination of amino protective group - - This reaction is carried out by conventional methods such as catalytic reduction method, liquidammoniaalkalimetal method, acid method, zinc acid method, base method, hydrazine method or the like. Among the above elimination methods, preferred one is selected according to kinds of the amino protective group. ¯ This reaction is usually conducted under icecooling to ambient temperature. (IV-2), Elimination of carboxy protective group This reaction is conducted by a conventional method such as hydrolysis and reduction or the like. Hydrolysis is preferably conducted in the presence of an acid or base under somewhat milder conditions such as cooling or warming and usually in a conventional solvent. Reduction, including chemical reduction and catalytic reduction, is conducted in a conventional manner. The reduction is usually conducted in a conventional solvent under somewhat milder conditions such as cooling or warming. (IV-3), Removal of hydrazino group A A protected carbazoyl of the formula - CONHNHY wherein Y is an amino protective group, can be removed by subjecting the compound (Ia) at first to the reaction of process (IV-1) for eliminating the amino protective group (i.e. Y) to give -CONHNH2 group and then subjecting the reaction product to the reaction of this step to give - COOH group. The reaction of this step is conducted in a conventional manner by treating the compound (Ia) with a conventional oxidising agent which is capable 'of oxidizing a grouts of the formula: - CONHNH2 to form into a group of-the formula : -COOH. The reaction is usually conducted in a conventional solvent under ice-cooling to ambient temperature. It is noted that this process includes the following cases of elimination of the carboxy protective and the amino protective group. that is, one case is that all of the carboxy protective groups and the amino protective group in the Compound (Ia) are simultaneously removed by a method to be employed to the reaction, and the other case is that the carboxy protective groups and the amino protective group are sequentially and stepwise removed by a method which is appropriately selected according to the kinds of the protective group to be removed. As to Process (IV) for elimination of protective group(s) (i.e. Processes IV-1 to IV-3), the followings are to be noted. That is, in case that the acyl group òr R1 has one or more protective group(s) for hydroxy, such a hydroxy protective group such as alkanoyl (e.g. acetyl, etc.) may be previously or later removed by subjecting the compound (I ) to elimination reaction of hydroxy protective group in a conventional manner such as reduction as illustrated in the Process IV-1 or IV-2. The starting compounds include known compounds (e.g. European Patent publication Nos. 11283) and-new compounds. Staid new compounds can be prepared by the similar methods thereto. AS to the object compound (I) and starting compounds which are prepared according'to the aforementioned processes, it is to be noted that each of said compounds includes one or more stereoisomers which is due to the asymmetric carbon atoms in their molecule and all of such isomers are included within the scope of this invention. The new peptide (I) and its pharmaceutically acceptable salts of this invention have been found to possess protective efficacy in experimental infection and antitumor activity. Accordingly, the new pep tide (I) and its pharmaceutically acceptable salts are useful for the therapeutic treatment of infectious diseases caused by pathogenic microorganism, especially gram-negative bacteria and gram-positive bacteria and fungi, and of tumor in human being and aminals. Further, the starting compounds are useful as intermediate for preparing Compound (I) having biologically active properties as mentioned above. For the purpose of showing pharmaceutical utility of the new peptide (I), pharmacological test data thereof are illustrated in the following. ,:PROTECTIVE EFFICACY IN EXPERINENTAL INFECTION IN I,N MICE : In determining the protective efficacy against experimental infections in mice, the test compound was dissolved in and diluted with sterile saline to provide prescribed concentration of drug. ,Male ICR-strain mice, aged 4 weeks were used in groups of ten mice. E. coli 22 was cultivated overnight at 370C on trypticase soy agar and then were suspended in a sterile saline to obtain microbial 9 cell concentration of 2.6 x 109 CFU/ml. Mice were inoculated intra-peritoneally with 8.7 x 107 CFU/mouse. Each of the test drugs was given intraperitoneally in various doses to a group of ten mice four days before challenge. Survival percent were found from the number of the surviving animals after three days of injection. Results are shown in Table. EMI36.1 <tb> <SEP> Test <SEP> Compound <SEP> Survival <SEP> (#) <SEP> <tb> <SEP> (Example <SEP> No.) <SEP> Dose <SEP> (mg/kg) <SEP> 0.1 <SEP> 1 <tb> <SEP> 0 <SEP> 0.01 <tb> <SEP> 1 <SEP> 10 <SEP> 70 <SEP> 50 <SEP> 90 <tb> <SEP> (Step <SEP> 2) <tb> <SEP> 2 <tb> <SEP> (Step <SEP> 2) <SEP> 10 <SEP> 50 <SEP> 70 <SEP> 90 <tb> <SEP> 3 <SEP> # <SEP> <SEP> 0 <SEP> 30 <SEP> 70 <SEP> 100 <tb> <SEP> (Step <SEP> 2) <tb> <SEP> 4 <SEP> 10 <SEP> 40 <SEP> 80 <SEP> 80 <tb> <SEP> (Step <SEP> 3) <tb> <SEP> 5 <SEP> 10 <SEP> 40 <SEP> 50 <SEP> 70 <tb> <SEP> 6 <tb> <SEP> (Step <SEP> 3) <SEP> * <SEP> 0 <SEP> 20 <SEP> 50 <SEP> 80 <tb> <SEP> 10 <SEP> 20 <SEP> 60 <SEP> 80 <SEP> 80 <tb> <SEP> (Step <SEP> 3) <tb> <SEP> 12 <tb> <SEP> (Step <SEP> 2) <tb> 13 <SEP> <tb> <SEP> (Step <SEP> 2) <SEP> 10 <SEP> 20 <SEP> 80 <SEP> 90 <tb> <SEP> 14 <SEP> * <SEP> # <SEP> <SEP> 0 <SEP> 40 <SEP> 70 <SEP> 60 <tb> <SEP> (Step <SEP> 3) <tb> <SEP> 14 <SEP> * <SEP> 0 <SEP> 30 <SEP> 70 <SEP> 60 <tb> <SEP> (Step <SEP> 4) <tb> <SEP> 17 <SEP> * <SEP> 0 <SEP> 10 <SEP> 0 <SEP> 50 <tb> <SEP> (Step <SEP> 2) <tb> <SEP> 19 <SEP> * <SEP> 0 <SEP> 30 <SEP> 30 <SEP> 70 <tb> <SEP> (Step <SEP> 3) <tb> <SEP> (Step <SEP> 2) <SEP> ## <SEP> 10 <SEP> 60 <SEP> 80 <SEP> 100 <tb> <SEP> 22 <SEP> * <SEP> 0 <SEP> 10 <SEP> 30 <SEP> 50 <tb> <SEP> (Step <SEP> 3) <tb> <SEP> 22 <SEP> *** <SEP> 20 <SEP> 80 <SEP> 80 <SEP> 50 <tb> (Step <SEP> 4) <tb> <SEP> 23 <SEP> * <SEP> 0 <SEP> 10 <SEP> 20 <SEP> 70 <tb> <SEP> (Step <SEP> 3) <tb> <SEP> 23 <tb> <SEP> (Step <SEP> 4) <tb> <SEP> 25 <tb> <SEP> (Step <SEP> 2) <tb> EMI37.1 <tb> <SEP> 26 <tb> (Step <SEP> 2) <SEP> 10 <SEP> 20 <SEP> 60 <SEP> 70 <tb> <SEP> 27 <SEP> 20 <SEP> - <SEP> . <SEP> 40 <SEP> 80 <SEP> 80 <tb> (Step <SEP> 2) <tb> <SEP> 28 <SEP> - <SEP> * <SEP> 0 <SEP> 70 <SEP> 90 <SEP> 90 <tb> (Step <SEP> 2) <tb> Note : * Observation of surviving ** animals : 1 day after infection ** Observation of surviving animals : 2 days after infection *** Infection: 1.8 x 107 cells/mouse **** Infection : 7.5 x 107 cells/mouse ANTITUMOR ACTIVITY (I) Methylcholanthlene-induced fibrosarcoma (Meth-A) was used. A mixture of the tumor cells (1 x 105) and the test compound was suspended in a 0.5 % methylcellulose saline solution. The' suspension was inoculated intradermally in male BALB/C mice. Three weeks after inoculation, tumor size was measured. Results are shown in the following table. EMI37.2 <tb> <SEP> Test <SEP> compound <SEP> Dose <SEP> Suppression <SEP> of <tb> <SEP> (Example <SEP> No.) <SEP> g/site <SEP> Meth-A <SEP> growth <tb> <SEP> 25 <SEP> 100 <SEP> 8/8 <tb> <SEP> (Step <SEP> 2) <tb> Control <SEP> 0 <SEP> 0/8 <tb> Note : Values gives Number of tumor-free mice/Number of mice tested, provided that when the perpendicular diameter of the tumor was less than 5 mm, the animal was defined as free of tumor. (2) Methylcholanthlene-induced fibrosarcoma (Meth-A) was used. The test compound was given to BALB/C mice intrapleurally 14 days before, and 1 hour and 3 days after the intrapleural inoculation of Meth-A, respectively. The cntitumor effect of the test compound was estimated by the prolongation of life-span in mice bearing Meth-A. Results are shown in the following table. EMI38.1 <tb> Test <SEP> compound <SEP> Dose <SEP> MST <SEP> T/C <SEP> <tb> (Example <SEP> No.) <SEP> pg/mouse <SEP> MsT <SEP> T/C <SEP> <tb> <SEP> I <tb> <SEP> 2 <tb> <SEP> (Step <SEP> 2) <SEP> 400 <SEP> 14.5 <SEP> 2.07 <tb> <SEP> Control <SEP> 0 <SEP> 7.0 <tb> <SEP> 3 <tb> <SEP> (Step <SEP> 3) <SEP> 400 <SEP> 11.5 <SEP> 1.64 <tb> <SEP> Control <SEP> 0 <SEP> 7.0 <tb> Note : MST means median survival time. -The pharmaceutical composition of this invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains an active substance of this invention in 'admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral applications. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The carriers which can be used are water, glucose, lactose, gun acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, collidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. The pharmaceutical compositions can also contain preservative or bacteriostatic agents to keep the active ingredient in the desired preparations stable in activity. The active object compound is included in the pharmaceuticÅal composition in an amount suffi cient to produce the desired therapeutic effect upon the process or condition of diseases. For applying this composition to humans, it is preferably to apply it by intravenous, intramuscular or oral administration. While the dosage or thera peutically effective amount of the object compound of this invention varies from and also depends upon the age and condition of each individual patient to be treated, a daily dose of about 0.1-100 mg of the active ingredient/kg of a human being or an animal is generally given for treating diseases, and an average single dose of about 50 mg, 100 mg, 250 mg, and 500 mg is generally administered. The following examples are given for purpose of illustrating this invention. In the following examples, starting compounds and object compounds are expressed by using the following abbreviations Lac : Lactoyl Ala : Alanyl Glu : Glutamyl Gly : Glycyl DAP : . a, # -Diaminopimelyl @@@ : benzyloxycarbonyl - Boc : : t-butoxycarbonyl Bzl : benzyl Ac : acetyl Su : N-hydroxysuccinimide Me : methyl Et : ethyl Lys : Lysyl Preparation 1 EMI41.1 D-AlaOH (2)(1.78 g) was dissolved in a mixture of water (40 ml), dioxane (40 ml) and triethylamine (4.04 g). To this solution was added Boc-L-Lys(E-Z)OSu (1)(9.26 g) and the resulting solution was left overnight at ambient temperature and then filtered. The filtrate was evaporated to give an oily residue which was dissolved in water. The solution was acidified with dil hydrochloric acid and then extracted with ethyl acetate. The organic layer was wahsed with water, dried over magnesium sulfate and then evaporated to give a white foam. The foam was dissolved in trifluoroacetic acid (30 ml) and reacted for 30 minutes at ambient tem perature. Excess trifluoroacetic acid was evaporated to give a paste which was dissolved in water. The solution was passed through HP20 column. The column was eluted with water and water-methanol (1:1), successively. The latter fractions ere com bined and evaporated to give L-Lys(c-Z)-D-AlaOH (3) (4.50 g). IR (Nujol) : 3350, 3300, 1685, 1660, 1640 cm 1 - NMR (CD30D) : 6 1.30-(3H, d, J=7Hz), 1.20-1.70 (6H, m), 2.86-3.50 (2H, m), 4.16 (1H, q, J=7Hz), 5.00 (2H, s), 7.30 (5H, s) Preparation 2 EMI42.1 Z-(L)-Boc-(D)-mesoDAP-(L)-GlyOMe-(D)-OMe (1) (0.66g) was dissolved in methanol (10 ml) and hydrogenated over 10% palladium charcoal (0.12 g). After removal of the catalyst by filtration, the filtrate was concentrated under reduced pressure to give Boc-(D)- mesoDAP-(L)-GlyOMe-(D)-OMe (2) (0.48 g). IR (CH2Cl2) : 3400, 3360, 1735, 1705, 1670 cm 1 NMR (CDCl3) # : 1.42 (9H, s), 1.3-2.2 (6H, m), 3.3-3.6 (1H, m), 3.77 (6H, s), 4.05 (2H, d, J=5Hz), 4.1-4.5 (1H, m) Preparation 3 EMI42.2 EMI43.1 Z-(L)-Boc-(D)-mesoDAP-(L)-GlyOMe-(D)-NHNHBoc (1)(1.8 g) was added to trifluoroacetic acid and the mixture was stirred for 15 minutes at room temperature. After evaporation of the solvent, the residue was dissolved - in 'methanol (50 ml) and treated with N-bromosuccinimide - (1.58 g), and the mixture was stirred for 10 minutes at - 00-50C and concentrated in vacuo. The residue was dis --solved in water (40 ml) and the excess reagent was de composed by adding 5% sodium bisulfite. The mixture was ¯neutralized to pH 9 with sodium bicarbonate, and extracted withsethyl acetate (40 ml). The extract was washed with - water and dried over magnesium sulfate, and the solvent was removed in vacuo. The residue was dissolved in a mixture of dioxane (20 ml) and water (10 ml). To this mixture triethylamine t0.66 g) and di-t-butylidacarbonate (1.42 g) was added and stirred for an hour at room temperature. After evaporation of the solvent, the residue was disssolved in ethylacetate (40 ml), and washed successively with 2.5% hydrochloric acid (15 ¯1) and water (20 ml), dried over magnesium sulfate and evaporated. The residue was pulverized with isopropyl- ether to give Z-(L)-Boc-(D)-mesoDAP-(L)-GlyOMe-(D)-OMe (2)(0.7 g). NMR (CD30D) ss : 1.43 (9H, s), 1.4-2.0 (6H, m), 3.72 (6H, s), 3.8-4.3 (4H, m), 5.12 C2H, s), 7.35 (SH, s) Preparation 4 EMI44.1 To a mixture of Z-(D)-mesoDAP-(D)-OME (1)(90 mg) and triethylamine (50 mg) in 50% aqueous dioxane was added di-t-butyldicarbonate (120 mg) and the mixture was stirred for overnight at room temperature. After evaporation of dioxane, the aqueous solution was washed with ether (10 ml) and acidified to pH3 with 5% hydrochloric acid and extracted with ethyl acetate (30 ml). The extract was washed with water and dried over magnesium sulfate. The solvent was removed under reduced pressure to give Boc-(L)-Z-(D)-mesoDAP-(D)-OMe (2)(110 mg). IRcm-1 in CH2Cl2 : 3390, 1730 (shoulder), 1710 NMR (CDCl3) a : 1.45 c9H, s), 1.4-2.0 (611, m), 3.68 (3H, s), 4.0-4.4 (2H, m), 5.08 (2H, s), 7.30 (5H, s) Preparation 5 EMI44.2 To a solution of diZDAP(D)-OMe (1)(2.20 g) in benzene ( 50 ml) was added thionyl chloride (5 ml) and the mixture was refluxed for an hour. The reaction mixture was concentrated under reduced pressure. The residual oil was dissolved in a mixture of dioxane (20 ml) and water (20 ml) and then stood overnight at room temperature. After concentration of dioxane, the concentrate was washed with ethyl acetate (20 ml). - The aqueous layer was concentrated to about 10 ml and neutralized to pH 5 with 5% aqueous sodium¯bicarbonate. The resulting crystalline solid was filtered and washed with water to give Z(D)-mesoDAP (D)-OMe (2)(0.58 g). IR cm-1 (Nujol) : 3100, 1745, 1695, 1610 NMR (DCt-D2O), 6: 1.3-2.3 (6H, m), 3.73 (3H, s), 4.0-4.5 (2H, m), 5.15 (2Hs s), 7.43 (5H, s) Preparation 6 EMI45.1 Z-(D)-mesoDAP-(D)-OEt (2) was prepared substantially in the'same manner as Preparation 5. IR cm L (Nujol) : 3300-2200, 1725, 1690, 1615 NMR (D2O-DCQ), 6: 1.25 (3H, t, J=7Hz), 1.5-2.2 (6H, m) , 3.9-4.5 (4H, m) , 5.13 (2H, s) , 7.42 (5H, s) Preparation 7 EMI45.2 a solution of diZ-mesoDAP-(D)-NHNHBoc (1)(30.3 g) jn, ethyl acetate (240 ml) was passed a -stream of hydrogen chloride gas, for 40 minutes under ice-bath cooling. The reaction mixture was stirred for an hour at the same temperature.- The precipitated crystals were filtered and washed with ether to give - diZ-mesoDAP-(D)-NHNH2-HCl (2)(24.2 g). IR, cm 1 (Nujol) : 3280, 3400-2200, 1720, 1680, -1660 SMR (CMSO-d6), 6:- 1.3-2.0 (611, m), 3.8-4.2 (2H, m), 5.04 (4H, s), 7.36 -(1OH, s) Preparation ss EMI46.1 Z-(L)-Boc-(D)-mesoDAP-(L)-GlyOMe-(D)-NHNHBoc (1)(9.57 g) was added to trifluoroacetic acid (96 ml) and the mixture was stirred for an hour at ambient temperature. After, evaporation of-trifluoroacetic acid, the residue was dissolved in 50% aqueous dioxane (180 ml) and the mixture was treated with N-bromosuccinimide (6.43 o). - After stirring for an hour under ice-bath cooling, the excess reagent was decomposed with 10% sodium bisulfite. The resulting solution was adjusted to pH 8 with 50% sodium bicarbonate and then a solution of di-t-butylcarbonate (8.56 g) in dioxane (35 ml) was added thereto. The resulting mixture was stirred for 20 hours at ambient temperature and evaporated. The aqueous solution was washed with ethyl acetate (100 ml) and adjusted to pH 3 with 5 hydrochloric acid and then extracted with ethyl acetate (250 ml). The extract was washed with water and dried over magnesium sulfate. The solvent was removed under reduced pressure to leave an oil, which.was chromatographed on silica gel t220 g) eluting with a mixture of chloroform and methanol (20:1) to give Z-(L)-Boc-(D) -mesoDAP- (L)- GlyOMe (2)(4.78 g). NMR (CD2OD), #: 1.47 (9H, s), 1.4-2.0 (6H, m), 3.73 -(3H, s), 3.97 (211, s), 4.0-4.35 (2H, m), 5.13 (2H, s), 7.37 (5H, s) Preparation 9 EMI47.1 A solution of Z-(L)-Boc-(D) -mesoDP- (L)-GlyOMe (1) (4.78 g) in a mixture of methanol (100 ml) and water (15 ml) was hydrogenated over 10t palladium-charcoal (1.45 g). After removal of the catalyst, the filtrate was evaporated to dryness under reduced pressure. The residue was pulverized with ether to give Boc-(D)mesoDAP-(L)-GlyOMe (2)(3.26 g). IR cm 1 (Nujol) : 3600-2200, 1740, 1680, 1220, 1170, 1050, 1030, 860 Preparation 10 EMI48.1 A solution of Z-(L)-Boc-(D)-mesoDAP-(L)-GlyOBzl (1) (13.7, g) in methanol (140 ml) was treated with ethereal diazomethane under ice-bath cooling. The mixture was stirred for an hour at the same temperature and concentrated under reduced pressure. The residue was pulverized with isopropylether to give Z-(L)-Boc-(D)-mesoDAP-(L). GlyOBzl-(D) OMe (2)(11.9 g). NMR (CD3oD), 6: 1.44 (9H, s), 1.3-2.0 (611, m), 3.68 (3H, s), 3.95 (2H, d, J=4Hz), 4.0-4.3 (2H, m), 5.06 (2H, s), 5.14 (2H, s), 7.30 (10H, s) Preparation 11 EMI48.2 A solution of Z-(L)-Boc-(D)-mesoDAP-(L)-GlyOBzl-(D)- Ole (1)(10.17 g) in a mixture of methanol (150 ml) and water (15 ml) was hydrogenated over 108 palladium charcoal (3.0 g) for 4 hours. After removal of the catalyst, the filtrate was evaporated to dryness under reduced pressure. The residue was pulverized with ether to give Boc-(D)-mesoDAP-(L)-GlyOH-(D)-OMe (2) (5.SS g). IR cm-1 (Nujol) : 3325, 1750, 1690, 1640, 1610 NOR (CD30D), d: 1.40 (9H, s), 1.5-2.0 (611, m), 3.70 (3H, s), 3.82 (ZH, s), 3.8-4.2 (ZH, m) Preparation 12 EMI49.1 To a solution of n-docosonoyl-L-Ala-D-Glu(&alpha;-OBzl)(1) (4.76 g) in a mixture of tetrahydrofuran (50 ml) and chloroform (100 ml) were added dicyclohexylcarbodiimide (1.56 g) and N-hydroxysuccinimide (0.87 g). The mixture was kept for 17 hours- at room temperature. The precipitate was filtered off and washed with chloroform (150 ml). The filtrate was concentrated in vacuo to give a crystal line residue, which was collected and washed with diisopropylether to give n-docosanoyl-L-Ala-D-Glu(&alpha;-OBzl)- OSu (2)(5.70 g).. -l IR (Nujol) : 3380, 1820, 1790, 1750, 1640 cm NMR (CDCl3-CD3OD), d: 0.91 (3H, m), 1.06-2.53 (47H, m), 2.84 (411, s) , 4.35-4.7; (2H, m), 5.19 (2H, s), 7.33 (5H, s) reparation 15 EMI50.1 Boc-L-Ala-D-Glu(&alpha;-OBzl)(1) (4.0 g) was dissolved in. trifluoroacetic acid (30 ml) and stirred for 2 hours at room temperature. The reaction mixture was concentrated in vacuo, and the residual oil was washed with ethyl ether. The oil was dissolved in methylenechloride (40 ml) and triethylamine (2.48 g) and methanol (12 ml) were added thereto. After the solution turned clean, n-docosanoic acid succinimidoester (4.28 g) and another 0.5 equivalent mole of triethylamine were added. After stirring for 19 hours, the reaction mixture was concentrated in vacuo. Water (15 ml) and 1N-hydrochloric acid (30 ml) were added to the solution to give a crystalline mass. The precipitate was collected and washed with water (50 m1) to give a crude crystal (5.78 g), which was purified by washing with hot -diisopropylether to give n-docosanoyl-L-Ala-D-Glu(&alpha;-OBzl) (2) (5.1 g). IR (Nujol) : 3300, 1725, 1700, 1650, 1630 cm 1 NMR (CDCQ3), : 0.88 (3H, m), 1.05-2.50 (4711, m), 4.3-4.8 (2H, m), 5.15 (2H, s), 7.32 (511, s) Preparation 14 EMI51.1 n-Tetracos anoylArMa-DGlu (a - OB zl) OSu (2) was prepared substantially in the same manner as Preparation 12. IR (Nujol) : 3380, 1820, 1790, 1745, 1630 cm 1 NMR (CDCl3-CD3OD), #: 0.87 (3H, m), 1.05-1.50 (51H, m), 2.82 (4H, s), 4.30-4.75 (2H, m), 5.17 (2H, s), 7.33 (5H, s) Preparation 15 EMI51.2 n-Tetracosanoyl-L-Ala-D-Glu(a-OBzl)(2) was prepared substantially in the same manner as Preparation 13. IR (Nujol) : 3360, 1740, 1710, 1640 cm 1 NMR (CDCl3-CD3OD), #: 0.88 (3H, m), 1.06-1.70 (47H, m), 2.00-2.50 (4H, m), 5.16 (2H, s), 7.36 (5H, s) Preparation 16 (1) Step 1 EMI52.1 To a mixture of L-Ala-D-Glu(#-OBzl)OMe hydrochloric acid salt (1)(2.9 g) and triethylamine (0.91 g) in acetonitrile (30 ml) was added D-lactic acid Nhydroxysuccinimide ester (2)(2.53 g) under ice-bath cooling. The mixture was stirred for 1.5 hours at ambient tenpercture. After evaporation of acetonitrile, the residue was dissolved in ethyl acetate. (70 ml), washed succesively with 2.5% hydrochloric acid (30 mlx2), water (30 ml), 2.5% sodium bicarbonate (30 ml) and water (30 ml x 2), dried over magnesium sulfate and then evaporated. The residue was chromatographed on silica gel column (60 g) eluting with a mixture of chloroform and ethyl acetate (1 : 1) to give D-Lac-L-Ala-D-Glu (#-OBzl) OMe (3) (2.23 g). NMR (CDCl3), #:1.30 (3H, d, J=7Hz), 1.43 (3H, d, J=7Hz), 2.0-2.7 (4H, m), 3.30 (1H, broad s), 4.73 (3H, s),- 4.0-4.8 (3H, m), 5.13 (2H, s), 7.35 (5H, s) (2) Step 2 EMI53.1 A solution of D-Lac-L-Ala-D-Glu(#-OBzl) OMe (3) (2.09 g) in methanol (100 ::il) was hydrogenated over 10% palladi charcoal (0.6 g). After removal of the catalyst, the filtrate was evaporated under reduced pressure to give D-Lac-L-Ala-D-GluOMe (4) (1.6 g). NMR (CDCl3), #: 1.40 (3H, d, J=7Hz), 1.43 (3H,d, J=7Hz), 1.9-2.6 (4H, m), 4.75 (3H, s), 4.18 (1H, q, J=7Hz), 4.3-4.6 (ZH,m) Preparation 17 EMI54.1 A solution of Z-(L)-Boc-(D)-mesoDAP-(L)-GlyOBzl (1) (3.8 g) in z mixture of methanol (100 ml) and water (10 ml) was hydrogenated over 10% palladium charcoal (0.18 g). After removal of the catalysts, the filtrate was evaporated to dryness under reduced pressure. The residue was pulverized with ether to give Boc-(D) mesoDAP-(L)-GlyOH (2)(2.10 g). NMR (CD3OD), #: 1.45 (9H, s), 1.3-2.1 (6H, m), 3.8-4.2 (4H, m) Preparation 18 (1) Step 1 EMI54.2 EMI55.1 A mixture of phosphorus oxychioride (120 mg) and N,N-dimethylformamide (1 ml) was stirred at 25-30 C for 3 hours and then was cooled to OOC. To the solution was added methylene chloride solution (2 ml) of 2,3;4,6-di-isopropylidene-2-keto-L-gulonic acid mono hydrate (1)(150 mg), keeping 'the temperature at 0 to 5 C for 30 minutes. The resulting solution was cooled at -20 to - 300C. On the other hand, D-Glu(OBzl)(2)(120 mg) was dissolved in a mixture of methylene chloride (100 ml) and bis-trimethylsilyl-acei2mide (800 mg). The solution thus prepared was added to the above solution at -20 to -30 C. The temperature of the mixture was raised to ambient temperature and then the mixture was stirred-for 15 hours. The reaction. mixture was evaporated in vacuo and extracted with ethyl acetate. The organic layer was washed with water (x2) and brine and then dried over magnesium sulfate. The solvent was evaporated to give an oily residue which was subjected to silica gel column The coltjr'. was eluted with chloroform and methanol (20:1). The solvent of the fraction containing, the object compound was evaporated to give 2,3;4,6-di- isopropylidene-2-keto-L-gulonoyl-Y-D-Glu (&alpha;-OBzl) OH (3) (220 mg). NMR (CDCl3), #: 1.33 (3H, s), 1.43 (3H, s), 1.53 (6H, s), 2.10-2.40 (4H, m), 4.15 (ZH, s), 4.33-4.66 (311, m), 4.73 (1H, t, J=7Hz), 5.16 (ZH, s), 7.33 (5H, s) (2) Step 2 EMI56.1 2,5;4,6-Di-isopropylidene-2-keto-L-gulonoyl-D-Glu (&alpha;-OBzl)OH (3) (950 mg) and N-hydroxysuccinimide (230 mg) was dissolved in tetrahydrofuran (10 ml). To the solution was added dicyclohexylcarbodiimide (410 mg) at OOC. The reaction mixture was stirred at 0 C and stood overnight in a refrigerator. The precipitates were filtered and washed with tetrahydrofuran. The filtrate was evaporated to give a viscous oil which was pulverized with diethylether to give 2, 3; 4,6-di-isopropylidene-2-keto-L gulonoyl-D-Glu(&alpha;-OBzl)OSu (4)(1.1 g ). NMR (CDCl3), #: 1.30 (3H, s), 1.40 (3H, s), 1.50 (6H, s), 2.77 (4H, s), 4.10-4.90 (6H, s), 5.16 (2H, s), 7.30 (5H, s) Preparation 19 EMI57.1 @ester of 1-N-n-hexyl-2,@,4,5-0-tetraacetyl-D-glucaramic acid with N-hydroxylsuccinimide (2) was prepared substantial ly in the same manner as step 2 of reparation @ 18. NMR (CDCl3), #: 0.7-1.1 (3H, m), 1.1-2.0 (8H, m), 2.10 (3H, s), 2.22 (9H, s), 2.88 (4H, s), 3.0-3.5 (2H, m), 5.2-6.0 (4H, m), 6.23 (1H, m) Preparation 20 EMI57.2 Boc-(L)-Z-(D)-mesoDAP-(D)-OEt (2) was prepared substantially in the same manner as Preparation 4. NMR (CDCl3), #: 1.17 (3H, t, J=7Hz), 1.40 (9H, s), 1.30-2.0 (6H, m), 4.13 (2H, q, J=7Hz), 4.25 (1H, m), 5.07 (2H, s), 5.30 (1H, broad), 7.25 (5H, s), 8.12 (1H, broad s) Preparation 21 EMI58.1 Boc-(L)-Z-(D)-mesoDAP-(L)-D-AlaOMe-(D)-OMe (2) was prepared substantially in the same manner as Preptra tion 1. IR (Nujol) : 3300, 1740, 1685, 1655 cm 1 EMI58.2 To n solution of diZ-mesoDAP-(D)-0Me (1)(37.0 g) in methylene chloride (200 ml) was added thionyl chloride (74 ml) and the mixture was refluxed for an hour. After evaporation of the solvent, the residue was dissolved in acetonitrile (200 ml). This solution was added to a mixture of D-alanine (21.0 g) and sodium carbonate (8.3 g) in a mixture of 0.5N sodium hydride (400 ml) and acetonitrile (200 1) under icebath cooling. After stirring for 30 minutes at the same temperature, the mixture was diluted with ethyl acetate (150 ml). The aqueous layer was evaporated and the organic layer was extracted with water (1;0 =1). The aqueous layer and the extract - were combined, washed with ethyl acetate and then, acidified to pH 4 with 20% hydrochloric acid, This solution was put on a column of HP 20 (700 ml). After washing with water, the column was eluted with a mixture of methanol and water (4:1) to give Z-(D)-mesoDAP-(L)- D-alaOH-(D)-OMe (2) (20.0 g). NMR (D2O-NaHCO3), #: 1.2-2.1 (6H, m), 1.35 c3H, d, J=7Hz), 3.73 (3H, s), 3.9-4.4 (3H, m), 5.10 C2H, s), 7.07 (SH, s) Preparation 23 EMI59.1 Z-(D)-mesoDAP-(L)-L-AlaOH-(D)-OBt (2) was prepared substantially in the same manner as Preparation 22. NMR (D2O-NaHCO3), d: 1.22 (3H, t, J=7Hz), 1.37 (3H, d, J=7Hz), 1.5-2.1 (6H, m), 3.8-4.4 (5H, m), 5.12 (2H, s), 7.40 (5H, s) Preparation 24 EMI59.2 Z-(D)-mesoDAP-(L)-D-AlaOH-(D)-OEt (2) was prepared substantially in the same manner as Preparation z NMR (D2O-NaHCO3), #: 1.23 (3H, t, J=8Hz), 1.35 (3H, d, J=7Hz), 1.1-2.0 (6H, m), 3.9-4.5 (5H, m), 5.15 (ZH, s), 7.34 (5H, s) Preparation 25 EMI60.1 Boc-(D)-mesoDAP-(L)-D-AlaOH-(D)-OMe (2) was prepared substantially in the same manner as Preparation 17. Preparation 26 EMI60.2 Z-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOBzl-(D)-OMe (2) was prepared substantially in the same manner as Preparations 3. NMR (CDCl3), #: 1.42 (9H, s), 1.0-2.1 (9H, s), 3.66 (3?i, s), 4.0-4.7 (3H, m) 5.07 (2H, s), 5.10 (2H, s), 7.29 (10H, s) Preparation 27 EMI62.1 To a solution of palmitoyl-L-Ala-D-Glu(OH)OBzl (1) (1.84 g) in a mixture of tetrahydrofuran (20 ml) and chloroform (30 ml) were added N-hydroxysuccinimide (425 mg) and dicyclohexylcarbodiimide (728 mg). The reaction mixture was kept for 18 hours at room tem- perature and the precipitate was filtered off and washed with chloroform. The filtrate was concentrated in vacuo and the diisopropylether was added to the residue. The product was collected and dried to afford palmitoyl-L-Ala-D-Glu(OSu)OBzl (2) (1.70 g). IR (Nujol) : 3300, 1805, 1780, 1745, 1640 cm 1 NMR (CDCl3, #): 0.89 (3H, m), 1.05-2.70 (35H, m), 2.80 (4H, s), 4.20-4.83 (2H, m), 5.15 (2H, s), 6.23 (1H, d, J=8Hz), 7.30 (5H, s). Preparation 28 EMI63.1 Trifluoroacetic acid (15 ml) was added to Boc- L-Ala-D-Glu-(OH)OBzl (1) (3.26 g) and the mixture was stirred for 20 minutes at room temperature, concentrated in vacuo and washed with diisopropylether. The oiZ was dissolved in a mixture of water (15 ml) and sodium bicarbonate was added until the pH of the solution became 8-9. The mixture of water (6 ml) and acetone (20 ml) was added to the solution and palmitoyl chloride (2.20 g) was added in one portion. After stirring for 30 minutes at room temperature, the pH of the solution was adjusted to 3 with lN-hydrochloric acid and the reaction mixture was concentrated. To the residue was added water (30 ml) and the precipitates was collected and. dried to give a crude, product, which was purified by column chromatography of Silicagel (90 g) with chloroform-methanol (30:1, v/v) as an eluent to give palmitoyl-L-Ala-D-Glu(OH)OBzl (2)(2.00 g). mp.131132 C. [&alpha;]D-23.38 C=0.2, CHCl3). IR (Nujol) : 3300, 1730, 1700, 1650, 1635 cm 1 NMR (CDCl3, #): 0.88 (3H, m), 1.1-1.75 (31H, m), 2.0-2.5 (4H, m), 4.4-4.8 (2H, m), 5.11 (2H, s), 7.34 (5H, s) Preparntion 29 EMI64.1 To a solution of Z-(L)-mesoDAP-(L)-D-AlaOBzl (1) (5.97 g) -in a mixture of water (60 ml), dioxane (60 ml) and triethylamine (2.73 g) was dropped a solution of di-tert-butyl carbonate (3.21 g) in dioxane (18 ml) at room temperature and the pH of the mixture was adjusted between 9 and 10 with triethylamine. After stirring for I hour, the mixture was diluted with water and ethyl acetate (100 ml) was added. The organic layer was extracted with water three tines and the aqueous layers were combined. The pH of the aqueous layer was adjusted to 4-5 with 5% hydrochloric acid and extracted with ethyl acetate. The extract was washed with brine, dried over magnesium sulfate and concentrated in vacuo. The resulting residue was crystallized with diiso propylether to give Z-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOBzl (2)(5.28 g). mp. -1430C (dec.). N"R (CD3OD) : #1.33 (2H, d, J=8Hz), 1.40 (9H, s), 1.2-2.0 (6H, m), 3.9-4.2 (2H, m), 4.40 (1H, q, J=8Hz), 5.05 (ZH, s), 5.10 (2H, s), 7.30 (10H, s). Preparation 30 EMI65.1 Z-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOBzl-(D)-NHNHBoc (1) (28 g) was added to trifluoroacetic acid (280 ml) and the mixture was stirred for 1 hour at room temperature. After evaporation of trifluoroacetic acid, the re- sidue was dissolved in a mixture of water (240 ml), 1N hydrochloric acid (40 ml) and dioxane (200 ml), and N-bromosuccinimide (16.4 g) was added at OOC. After stirring for 0.5 hours at the same temperature, the reaction mixture was treated with an aqueous solution of sodium sulfite and concentrated in vacuo. To the residue was added 30% aqueous sodium hydroxide until the pH of the mixture reached to 4-5. The result- ing precipitate was collected and washed with water to give Z-(L)-mesoDAP-(L)-D-AlaOBzl (2). IR (Nujol) : 3280, 1725, 1685, 1640 cm 1 NMR (DMSO-d6) : 6 1.34 (3H, d, J=8Hz), 1.2-2.0 (6H, m), 4.37 (1H, q, J=8Hz), 5.08 (2H, s 5.16 (2H, s), 7.43 (10H, s) Example 1 (1) Step 1 EMI66.1 L-Lys(#-Z)-D-AlaOH (2)(0.915 g) was dissolved in a mixture of methylene chloride (40 ml) methanol (40 ml) and triethylamine (0.53 g). To this solution was added n-octanoyl-D-Glu(&alpha;-OBzl)-&gamma;- OSu (l)(1.20 g) and the resulting solution'was left overnight at ambient temperature. The reaction mixture was evaporated to give a paste, to which were added water (50 ml), ether (50 ml) and IN hydrogen chloride. The resulting mixture was stirred well and ether was evaporated to separate crystals from the aqueous layer. The crystals were filtered, washed with water and then dried to give n-octanoyl-&gamma;-D-Glu(&alpha;-OBzl)-L-Lys (#-Z)-D- AlaOH (3) (1.50 g). IR (Nujol) : 3300, 1725, 1685, 1650, 1630 cm- NMR (DMSO-d6) : # 0.84 (3H, t, J=7Hz), 1.00-2.40 (25H, m), 2.84-3.12 (2A, m), 4.10-4.30 (3H, m), 5.00 (2H, s), 5.10 (2H, s), 7.32 (10H, s), 8.10 (2H, t, J=8Hz), 8.84 (1H, d, J=8Hz) (2) Step 2 EMI67.1 Octanoyl-&gamma;-D-Glu(&alpha;-OBzl)-L-Lys(#-Z)-D-AlaOH (3)(1.20 g) was dissolved in acetic acid (50 ml) and hydrogenated over palladium black (150 mg). The catalyst was removed -by filtration and the filtrate was evaporated to give a paste. The paste was allowed to stand to give crystals The crystals were washed throughly with diethyl ether to give octanoyl-&gamma;-D-Glu(&alpha;-OH)-L-Lys-D-AlaOH (4)(0.80 g).. +41.7 (C=0.2, acetic acid) IR (Nujol) : 3360, 1710 (sh), 1640 cm-1 NMR (D2O): 6 0.84 (3H, obscure t, J=7Hz), .1.00-2.50 (25H, m), 2.80-3.10 (2H, m), 4.00-4.40 (3H, m) Example 2 EMI67.2 EMI68.1 Stearoyl-&gamma;-D-Glu(&alpha;-OBzl)-L-Lys(#-Z)-D-AlaOH (3) was prepared substantially in the same manner as step (1) of Example 1. NMR (DMSO-d6) : 6 0.84 (3H, t, J=7Hz), 1.00-2.40 (45H, m), 2.80-3.10 (2H, m), 4.00-4.80 (3H, m), 5.00 (2H, s), 5.08 (2H, s), 7.32 (10H, s), 7.80 (1H, d, J=8Hz), 8.08 (2H, t, J=8Hz) (2) Step 2 EMI68.2 S te aroyl - y - D- G lu (a - OH) - L - Ly s - D- Al aOH (4) -was prepared substantially in the same manner as step (2) of Example 1. [&alpha;]D = -11.10 (C=0.21, acetic acid) IR (Nujol) : 3350, 1730, 1640 cm 1 NMR (NaOD-D2O), #: 0.68-2.80 (50H, m), 4.10-4.50 (3H, m) Example 5 (1) Step 1 EMI69.1 Stearoyl-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP-(1)(2.20 g) was dissolved in tetrahydrofuran (50 ml), and ethereal diazomethane solution was added thereto until pale yellow of the solution persisted. After 10 minutes, excess diazomethane was destroyed by adding acetic acid thereto. The resulting solution was evaporated to give a white crystalline residue, which was washed with diisopropyl ether to give stearoyl-y-D-Glu(rY-03zl)- (L)-Boc-(D)-mesoDAP-(L)-(OMe)-(D)-(OMe) (2) (2.10 g). IR (Nujol) : 3300, 1740, 1680, 1640 cm-1 NMR (CDCl3), #: 0.83-2.50 (45H, m), 3.71 (3H, s), 3.75 (3H, s), 4.10-5.00 (3H, m), 5.20 (2H, s), 7.36 (5H, s) (2) Step 2 EMI69.2 Stearoyl-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP-(L)- (OMe)-(D)-(OMe) (2)(0.90 g);was dissolved in a mixture of acetic acid (10 ml) and hydrogen chloride-saturated acetic acid (4 ml). The solution was allowed to stand for 15 minutes at ambient temperature and then evaporated to give a crystalline reside. The crystalline residue was throughly washed with isopropyl ether to give stearoyl-&gamma;-D-Glu(&alpha;-OBzl)-(L)- mesoDAP-(L)-(OMe)-(D)-(OMe) hydrochloric acid salt (3). IR (Nujol) : 3300, 1740, 1640 cn1 NMR (DMSO-d6), #: 0.76-2.40 (45H, m), 3.64 (3H, s), 3.76 (3H, s), 3.84-4.40 (3H, m), 5.12 (2H, s), 7.38 (5H, s) (3) Step 3 EMI70.1 Stearoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-(OMe)-(D)-(OMe) (4) was prepared substantially in the same manner as step (2) of Example 1. &alpha;]@ = +3.901 (C=O.2, acetic acid) IR (Nujol) : 3300, 1730, 1640, 1600 cm-1 NMR (DMSO-d6), #: 0.70-2.32 (45H, m), 3.62 (3H, s), 3.74 (3H, s), 3.80-4.32 (3H, m), 8.02 (1H, d, J=8Hz), 8.30 (1H, d, J=8Hz) Example 4 (1) Step 1 EMI71.1 To a suspension of n-docosanoyl-L-Ala-D-Glu(&alpha;-OBzl)-&gamma;- OSu (1) (2.91 g) in methylene chloride (50 ml) were added triethylamine (0.89 g) and Boc-(D)-mesoDAP-(L)-D- AlaOH (2) (1.44 g). The mixture was kept for 66 hours at ambient temperature and then concentrated in vacuo. To the residue were added water (100 ml), lN hydrochloric acid (10 ml) and ethylether (30 ml). The resulting mixture was stirred for 15 minutes and ethylether was removed. The precipitate was collected by filtration and then washed with water to give a crude product which was washed with diisopropylether to give n docosanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP- (L)-D-AlaOH (3)(3.60 g). IR (Nujol) : 3300, 1720, 1680, 1630 cm-1 NMR (CDCl3-CD3OD), #: 0.94 (3H, m), 1.1-2.5 (65fI, m), 5.21 (2H, s), 7.38 (5H, s) (2) Step 2 EMI72.1 To a solution of n-docosanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)- Boc--(D)-mesoDAP-(L)-Ala'OH (3) (1.5 g) in a mixture of tetrahydrofuran (40 ml) and chloroform (20 ml) was added 0.6M dia=omethane in ethylether (10 ml). The resulting mixture was stirred for 30 minutes at ambient temperature and then the excess reagent was decomposed with acetic acid. The reaction mixture was concentrated and the residue was washed with ethylether and collected by filtration to give n-docosanoyl-L-Ala- &gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP-(L)-D-Ala(OMe)-(D)- OMe (4)(1.36 g). NMR (CDCl3-CD3OD), 6: 0.90 (3H, m), 1.1-2.6 (65H, m), 3.71 (3H, s), 3.74 (3H, s), S.l9 (2H, s), 7.48 (SH, s) (3) Step 3 EMI73.1 n-Docosanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP- (L)-D-AlaOMe-(D)-OMe (4)(1.25 g) was dissolved in acetic acid (2Q ml) and hydrogenated under an .atmospheric pres sure of hydrogen over 10% palladium charcoal. After removal of the catalyst, acetic acid (S ml) saturated with hydrogen chloride was added to the filtrate. .rne resulting mixture was kept for 5 hours at ambient temperature and concentrated in vacuo to give a crystalline residue, which was collected and washed with diisopropylether to give n-docosanoyl-L-Ala-&gamma;-D- Glu(&alpha;-OH)-(L)-D-AlaOMe-(D)-OMe hydrochloric acid salt (5)(1.08 g). [&alpha;]D = -11.42 (C=0. O, acetic acid) IR (Nujol) : 3380, 1745, 1630 cm 1 NMR (DMSO-d6), # : 0.87 (5H, m), 1.05-2.45 (56H, m), 3.63 (3H, s), 3.75 (3H, s) Example 5. EMI74.1 n-Docosanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D- AlaOH (2) was prepared substantially in the same manner as step 3 of Example 4. = - 19.54 (C=0.20, acetic acid) IR (Nujol) : 3380, 1740, 1630 cm-1 NMR [NaOD-D2O), d: 0.91 (3H, m), 3.25 (lii, m), 4.0-4.6- (5H, m) Example 6 (1) Step 1 EMI75.1 n-Tetracosanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)- mesoDAP-(L)-D-AlaOH (3) was prepared substantially in the same manner as step 1 of Example 4. IR (Nujol) : 3300, 1720, 1680, 1630 cm 1 NMR (CDCl3-CD3OD), #: 0.90 (3H, m), 1.05-2.50 (69H, m), 5.15 (2H, s), 7.34 (5H, s) (2) Step 2 EMI76.1 n-Tetracosanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)- mesoDAP-(L)-D-AlaOMe-(D)-OMe (4) was prepared sub stantially in the same manner as step 2 of Example 4. IR (Sujol) : 3300, 1735, 1685, 1630 cm NMR (CDCl3-CD3OD), #: 0.89 (3H, m), 1.05-2.50 (69H, m), 3.69 (3H, s), 3.73 (3H, s), 5.18 (2H, s), 7.42 (15H, s) (3) Step 3 EMI76.2 n-Te.racosanoyl-L-Ala-y^D-Glu(a-OH)-(L)-mesoDAP-(L)- D-AlaOMe-(D)-OMe hydrochloric acid salt (5) was prepared substantially in the same manner as step 5 of Example 4. [&alpha;]D = -14.01 (C=0.26, acetic acid) IR (Nujol) : 3380, 1745, 1630 cm-1 NMR (DMSO-d6), #: 0.85 (3H, m), 1.0-2.4 (60H, m), 3.60 (3H, s), 3.72 (3H, s) (4) Step 4 EMI77.1 D-Tetracosanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- D-AlaOH (6) was prepared substantially in the same manner as step 3 of Example 4. IR (Nujol) : 3280, 1730, 1630 cm 1 NMR (D2O+NaHCO3), #: 0.88 (3H, m), 3.72 (1H, m), 3.95-4.6 (4H, m) Example 7 EMI77.2 EMI78.1 D-Lac(OAc)-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP- (L)-GlyOMe-(D)-OMe (3) was prepared substantially in the same manner as step 1 of Example 4. IR (Nujol): 3250, 1720, 1680, 1630 cm 1 NMR (CD3OD), #: 1.2-1.9 (17H, m), 2.12 (3H s), 1.9-2.6 (2H, m), 3.70 (6H, s), 3.97 (2H, s), 4.0-4.6 (4H, m), 4.98 (1H, q, J=7Hz), 5.18 (2H, s), 7.35 (SH, s) Example 8 (1) Step 1 EMI78.2 D-Lac(OAc)-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Z-(D)-mesoDAP. (L)-GlyOMe-(D)-OMe (3) was prepared substantially in the same manner as step 1 of Example 4. IR (Nujol) : 3260, 1735, 1635 cm NMR(CDCl3), #: 1.1-2.5 (10H, m), 1.35 (3H, d, J=7Hz), 1.42 (3H, d, J=7Hz), 2.08 (3H, s), 3.60 (3H, s), 3.67 (3H, s), 3.94 (2H, d, J=7Nz), 4.1-4.8 (4H, m), 4.9-5.2 (1H, m), 5.06 (2H, s), 5.09 (2H, s), 7.30 (10H, s) (2) Step 2 EMI79.1 D-Lac(OAc)-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Z-(D)-mesoDAP-(L)- GlyOMe-(D)-OMe (3)(1.32 g) was hydrogenated in acetic acid (15 ml) over 10% palladium charcoal (0.4 g) for. 1.5 hours under an atmospheric pressure of hydrogen at ambient temperature. After completion of the reaction, the catalyst was filtered off and the filtrate was evaporated to dryness. The residue was pulverized with ether to give D-Lac(OAc)-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- mesoDAP-(L)-GlyOMe-(D)-OMe (4) (1.1 g). NMR (D2O), #: 1.2-2.3 (10H, m), 1.45 (3H, d, J=7Hz), 1.47 (3H, d, J=7Hz), 3.77 (3H, s), 3.897 (3H, s), 4.03 (2H, s), 4.1-4.5 (4H, m), 5.07 (1H, q, J=7H:) Example 9 (1) Step 1 EMI80.1 D-Lac(OAc)-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP- (L)-GlyOH-(D)-OMe (3) was prepared substantially in the same manner as step 1 of Example 4. IR (Nujol) : 3270, 1735, 1650 cm 1 NMR (CDCl3), #: 1.2-2.7 (16H, m), 1.43 (9H, s), 2.12 (3H, s), 3.70 (3H, s), 3.8-4.5 (7H, m), 4.9-5.3 (1H, n), 5.13 C2H, s), 7.32 (5H, s) (2) Step 2 EMI80.2 D-Lac(OAc)-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- (L)-GlyOH-(D)-OMe (4) was prepared substantially in the same manner as step 2 of Example 8. IR (Nujol) : 3300, 1725, 1650 cm-1 NMR (CD3OD), #: 1.3-2.6 (16N, m), 1.43 (9H, s), 2.11 (3H, s), 3.70 (3H, s) , 3.93 (2N, s) 4.2-4.6 (4H, m), 5.08 (1H, q, J=7Hz) Example 10 (1) Step 1 EMI81.1 Heptanoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D-AlaOH (1) (1.00 g) was dissolved in the mixture of water (10 ml) and dioxane (20 ml). Triethylamine (730 mg) and 2-(tert-butoxycarbonyloxyim,no)-2-phenylacetonitrile (640 mg) was added to the solution. After stirring for 16 hours at ambient temperature, the reaction mixture was concentrated. To the residue was added waters (30 Ml), 1N hydrochloric acid (8 ml) and ethyl acetate. The organic layer was separated and washed with brine, dried over magnesium sulfate and con cent- rated in vacuo to give an oily residue, which was treated with ethylether and diisopropylether to give heptanoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc(D)-mesoDAP-(L)-D- AlaOH (2)(925 mg). IR (Nujol) : 3300, 1720, 1637 cm-1 NMR (CD3OD), 6: 0.90 (3H, in), 1.1-2.6 (23H', m), 3.70 (1H, t, J=6Hz), 3.90-4.65 (3H, m) t2) Step 2 EMI82.1 Heptanoyl-y-D-Glu(a-OMe) - CL) -Boc- (D) -mesoDAP- (L) -D- AlaOMe-(D)-OMe (3) was prepared substantially in the same manner as step 2 of Example 4. IR (Nujol) : 3300, 1735, 1685, 1630 cm 1 NMR (CD3OD), #: 0.91 (3H, m), 1.15-1.90 (16H, m), 2.00-2.45 (4N, m), 3.71 (9H, s), 4.06 (1H, m), 4.24-4.56 (3H, m) (3) Step 3 EMI83.1 Heptanoyl-&gamma;-D-Glu(&alpha;-OMe)-(L)-mesoDAP-(L)-D-AlaOMe-(D)- OMe (4) was prepared substantially in the same manner as step 3 of Example 4. IR (Nujol) : 3320, 3080, 1740, 1635 cm-1 NMR (CD3OD), #: 0.92 (3H, m), 1.16-2.46 (26H, m), 3.74 (9H, s), 4.21-4.60 (4H, m) Example 11 (I) Step 1 EMI83.2 Octanoyl-&gamma;-D-Glu(&alpha;-OMe)-(L)-Boc-(D)-mesoDAP-(L)-D- AlaOMe-D-OMe (2) was prepared substantially in the same manner as step 2 of Example 4. IR (Nujol) : 3370, 1750, 1690, 1640 cm-1 NMR (CDCl3), #: 0.89 (3H, m), 1.05-2.75 (37H, m), 3.72 (9H, s), 4.20 (1H, m), 4.35-4.75 (3H, m), 5.35 (1H, d, J=8Hz), 6.75 (lH, d, J=8Hz), 6.85 (lH, d, J=8Hz), 7.42 (1H, d, J=7Hz) (2) Step 2 EMI84.1 Octanoyl-&gamma;-D-Glu(&alpha;-OMe)-(L)-mesoDAP-(L)-D-AlaOMe-(D)- OMe hydrochloric acid salt (3) was prepared substantially -in the sarie manner as step 3 of Example 4. IR (Nujol) : 3280, 1735, 1630 cm 1 NMR (CD3OD), #: 0.89 (3H, m), 1.2-2.5 (22H, m), 3.72 (6H, s), o.86 (3H, s), 4.07 (1H, t, J=6Hz), 4.19-4.65 (3H, m) Example 12 (1) Step 1 EMI85.1 D-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP-(L)- GlyOMe (3) was prepared substantially in the same manner as step 1 of Example 4. NMR (CDJOD), #: 1.38 (6H, d, J=7Hz), 1.47 (9H, s), 1.3-2.5 (10H, m), 3.75 (3H, s), 4.00 (2H, s), 4.0-4.6 (5H, m), 5.20 (2H, s), 7.40 (5H, s) (2) Step 2 EMI85.2 D-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOMe (4) was prepared substantially in the same manner as step 3 of Example 4. IR cm-1 Nujol : 3280, 1740, 1640 NMR (D2O), #: 1.38 (3H, d, J=7Hz), 1.41 (3H, d, J=7Nz), 1.3-2.5 (1OH, m), 3.75 (3H, s), 3.98 (2H, s), 4.0-4.6 (5H, m) Example 13 (l) Step 1 EMI86.1 D- Lac- L-Ala-y- D- Glu(a- OBzl) - (L) -Boc- (D) -mesoDAP- (L) GlyOH-(D)-OMe (3) was prepared substantially in the same manner as step 1 of Example 4. NMR (CD3OD), #: 1.42 (9H, s), 1.2-2.5 (16H, m), 3.70 (3H, s), 3.92 (2H, s), 4.0-4.6 (5H, m), 5.17 (2H, s), 7.35 (5H, s) (2) Step 2 EMI87.1 D-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH-(D)- OMe (3) was prepared substantially in the same manner as step 3 of Example 4. IR (KBr) : 3700-2500, 1730, 1650 cm-1 NMR (D20), 6 1.37 (3H, d, J=7Hz), 1.40 (3H, d, J=7Hz), 1.3-2.5 (1OH, m), 3.80 (2H, s), 3,83 (3H, s), 4.0-4.6 (5H, m) Example 14 (1) Step 1 EMI88.1 To an ice-cooling solution of L-Ala-D-Glu(a-OBzl)- (L)-Z-(D)-mesoDAP-(L)-GlyOH-(D)-NHNHZ (1) (1.23 g) and triethylamine (0.30 g) in a mixture of acetone (12 ml) and water (2 ml) was added a solution of ester of l-N-n-hexyl- 2,;,4,5-O-tetraacetyl-D-glucaramic acid with N-hydroxylsucci- nimide (2)(0.84 g) in acetone (12 ml). The mixture was stirred overnight, allowing the temperature of the mixture to reach to ambient temperature. After evaporation, the residue was added to a mixture of water (50 ml) and ethyl acetate (100 ml). The organic layer was washed with aqueous sodium bicarbonate (30 ml), water (30 ml), 10% hydrochloric acid (30 ml) and water (30 ml x 2) and then dried over magnesium sulfate. The solvent was removed in vacuo to give l-N-n-hexyl-2,3,4,5-O-tetraacetyl-D-glucaramsyi- L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Z-(D)-mesoDAP-(L)-GlyOH-(D)- NHNHZ (3) (1.15 g). NMR (DMSO-d6), 6: 0.7-1.0 (3H, m), 1.1-1.7 (19H, m), 1.7-2.3 (2H, m), 1.96 (3H, s), 2.00 (3H, s), 2.07 (3H, s), 2.12 (3H, s), 2.8-3.1 (2H, m), 3.8-4.5 (1OH, m), 5.00 (2H, s), 5.06 (2H, s), 5.10 (2H, s), 5.30. (1H, m), 5.60 (1H, m) , 7.34 (15H, s), 7.7-8.2 (5H, m) , 8.40 (1H, m), 9.98 (1H, s) (2) Step 2 EMI89.1 <tb> Compound <SEP> (3) <SEP> <tb> EMI89.2 l-N-n-hexyl-2,3,4,5-0-tetraacetyl-D-Glucaramoyl-L- Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH-(D)-NHNH2 (4) was prepared substantially in the same manner as step 2 of Example 1. NMR (CD3OD), a: 0.8-1.1 (3H, m), 1.1-2.5 (21H, m), 2.03 (6H, s), 2.17 (3H, s), 2.23 (3H, s), 3.0-3.6 (2H, m), 3.7-4.8 (6H, m), 5.1-6.0 (9H, m) (3) Step 3 EMI90.1 <tb> Compound <SEP> (4) <tb> EMI90.2 To an ice-cooling solution of 1-N-n-hexyl-2,3,4,5-0- tetraacetyl-D-glucaramoyl -L-Ala-y-D-Glu(a-OH)-(L) mesoDAP-'(L)-GlyOH-(D)-NHNH2 (4)(0.64 g) in a mixture of 10% hydrochloric acid (3 ml) and 1,4-dioxane (6 ml) was added N-bromosuccinimide (0.2 g). After stirring for an hour at ambient temperature, the mixture was treated with sodium bisulfite and then adjusted to pH 4 with aqueous sodium carbonate. After evaporation, the residue was dissolved in 1N hydrochloric acid (2 ml) and put on a column of HP-20 (40 ml). After removal of inorganic salts with water, the product was obtained by eluting with 70% methanol. The eluate was lyophilized to give 1-N-n-hexyl-2,3,4,S- O-tetraacetyl- D-glucaram,oyl -L-Ala-y-D- GluCa-ON) - CL) - mesoDAP-(L)-GlyOH (5) (0.43 g). NMR (D2O), a: 0.7-1.0 (3H, m), 1.0-1.6 (19H, m), 1.6-2.5 (2N, m), 2.14 (3H, s), 2.16 (3H, s), 2.22 (3H, s), 2,24 (3H, s), 3.0-3.3 (2H, m), 3.76 (lH, m), 4.0-4.6 (5H, m), 5.1-5.8 (4H, m) (4) Step 4 EMI91.1 <tb> Compound <SEP> (5) <tb> EMI91.2 To an ice-cooling solution of l-N-n-hexyl-2,3,4,5-Otetraacetyl-D-glucaramoyl -L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- mesoDAP-(L)-GlyOH (5)(0.33 g) in 508 methanol was added 2N potassium carbonate (2 ml). The mixture was stirred for two hours at the same temperature and then acidified to pH 4 with 10% hydrochloric acid. After evaporation, the residue was dissolved in 1N hydrochloric acid (1 ml) and put on a column of HP-20 (15 ml). Inorganic salts were removed with water and then eluted with 80t methanol. The eluate was lyophilized to give l-N-n-hexyl-D-glucaramoyl -L-Ala-&alpha;-D- Glu(a-OH)- (L) -mesoDAP- (L)-GlyOH (6)(0.26 g). IR (Nujol) : 3300, 1720, 1640, 1540, 1230 m-1 NMR (D2O), 6: 0.7-1.0 (3H, m), 1.0-2.5 (21H, m), 3.1-3.5 (2H, m), 3.5-4.5 (10H, m) Example '15 (1) Step 1 EMI92.1 D-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OMe)-(L)-Boc-(D)-mesoDAP-(L)- GlyOH (3) was prepared substantially in the same manner as step 1 of Example 4. NMR (CD3OD), 6: 1.46 (9H, s), 1.2-2.4. (1OH, m), 3.72 (3H, s), 3.93 (2H, s), 4.0-4.6 (5H, m) (2) Step 2 EMI92.2 D-Lac-L-Ala-Y-D-Glu(a OMe)-(L)-mesoDAP-(L)-GlyOH (4) was prepared substantially in the same manner as step 3 of Example 4. NMR (D2O), d: 1.40 (3H, d, J=7Hz), 1.45 (3H, d, J=7Hz), 1.3-2.6 (10H, m), 3.77 (3H, s), 3.87 C2H, s), 4.2-4.6 (4H, m) Example 16 EMI93.1 D-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OMe)-(L)-mesoDAP-(L)-GlyOMe (3) was prepared substantially in the same manner as steps 1 and 3 of Example 4. NMR (D2O), #: 1.36 (3H, d, J=7Hz), 1.42 (3H, d, J=7Hz), 1.2-2.4 (10H, m), 3.72 (6H, s), 3.98 (2H, s), 4.2-4.5 (4H, m) Example 17 (1) Step 1 EMI94.1 D-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OMe)-(L)-Boc-(D)-mesoDAP-(D)- OMe-(L)-GlyOH (3) was prepared substantially in the same manner as step 1 of Example 4. IR cm 1 Nujol: 3300, 1730, 1660 NMR (CD3OD), #: 1.47 (9H, s), 1.4-2.5 (16H, m), 3.73 (6H, s), 3.95 (2H, s), 4.0-4.6 (SN) (2) Step 2 EMI95.1 D-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OMe)-(L)-mesoDAP-(D)-OMe-(L)-GlyOH(4) was prepared substantially in the same manner as Step 3 of Example 4. [&alpha;]D = -22.9 (C=0.2, H2O) IR cm Nujol: 3400, 1745, 1650 NMR (D20), a: 1.33 (3H, d, J=7Hz), 1.40 (3H, d, J=7Hz), 1.2-2.6 (1OH, m), 3.77 (3H, s), 3.83 (3H, s), 4.0-4.6 (5H, m) Example 18 (1) Step 1 EMI95.2 EMI96.1 2,3;4,6-diisopropylidene-L-2-ketogulonoyl-y-D- Glu(a-OBzl)-L-Lys(Z)-D-AlaOH (3) was prepared substantially in the same manner as step 1 of Example 1. IR (Nujol), : 3300, 1750-1620, 1250-1060-1 (2) Step 2 EMI96.2 2,3;4,6-Diisopropylidene 2-ketogulonoyl-y-D Glu(&alpha;-OBzl)-L-Lys(Z)-D-AlaOH (3)(0.9 g) was dissolved in dioxane. To the solution was added conc. hydrochloric acid (5 ml), and the mixture was stirred for 20 hours and then adjusted to pH 6-7 with aqueous sodium bicarbonate solution. The resultant mixture was concentrated in vacuo and the residue was dissolved in water. The solution was subjected to carbon column (30 ml). The column was eluted with methanol and ethanol (1:1). The fractions containing the object compoud (4) were collected and the solvent was evaporated to give a foam which was lyophilized to give 2-keto-L-gulonoyl-&gamma;-D-Glu(&alpha;-OBzl)-L-Lys-D-AlaOH (4)(400 mg). NMR (D2O), d: 1.32 (3H, d, J=7Hz), 3.15 (2H, t, J=7Hz), 3.66-4.S0 (8H, m), 5.10 (2H, s), 7.43 (SH, s) (3) Step 3 EMI97.1 2-Keto-L-gulonoyl-y-D-Glu(a-OH)-L-Lys-D-AlaOH (5) was prepared substantially in the same mariner as step 2 of Example l. NMR (D2O), 6: 1.36 (3H, d, J=7Hz), 3.05 (2H, t, J=7Hz), 3.70-4.50 (8H, m) Example 19 (1) Step 1 EMI98.1 2,3;4,6-di-isopropylidene-2-keto-L-gulonoyl-y-D- Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOH (3) was prepared substantially in the same manner as step 1 of Example 1. IR (Nujol) , : 3300, 1730, 1680, 1520, 1250-1060 cm 1 NMR (CD3OD), d: 1.06 (3H, s), 1.20 (3H, s), 1.47 (15H, s), 4.16-4.50 (9H, m), 5.20 (2N, s), 7.40 (SH, s) (2) Step 2 EMI99.1 2-Keto-L-gulonoyl-y-D-Glu(a-OBzl) - (L) -mesoDAP- (L) -D AlaOH (4) was prepared substantially in the same manner as step 2 of Example 18. IR (Nujol), : 3300, 1730, 1650, 1530, 1220, 1180, 1050 cm 1 NMR (D2O), a: 1.33 (3H, d, J=8Hz), 3.66-4.50 (8H, m), 5.30 (2H, s), 7.47 (5H, s) (3) Step 3 EMI99.2 2-Keto-L-gulonoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D- AlaOH (5) was prepared substantially in the same manner as step 2 of Example 1. IR (Nujol), : 3300, 1720, 1670 cm 1 NMR (D2O), 6: 1.38 (3H, d, J=7Hz), 1.70-2.50 (1OH, m), 3.60-4.40 (8H, m) Example 20 (1) Step 1 EMI100.1 Stearoyl-@-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Z-(D)-mesoDAP-(D)-OEt (L)-D-AlaOEt (3) was prepared substantially in the same manner as step 1 of Example 4. IR (Sujol) : 3280, 1750, 1710, 1650 cm 1 NMR (CDCl3),: #: 0.87 (3H, m), 3.96-4.60 (9H, m), 5.10 (2H, s), 5.13 (2H, s), 7.32 (1OH, s) (2) Step 2 EMI101.1 Stearoyl-L-Ala-y-D-Glu(a-OBzl) - CL) -Z- (D) -mesoDAP- (D)-OBt-(L)-D-AlaOBt (3)(584 mg) was dissolved in acetic acid (20 ml) and hydrogenated under 2.5 atmospheric pressures of hydrogen over 10% palladium charcoal. After removal bf the catalyst by filtration, the filtrate was evaporated in vacuo. To the residue was added hexane to give crystals which were washed with hot isopropylether to give stearoyl-L-Ala-y-D Glu(&alpha;-OH)-(L)-mosoDAP-(D)-OBt-(L)-D-AlaOBt (4) (340 mg). IR (Nujol) : 3290, 1740, 1630 cm 1 NMR (CF3COOH), ô: 0.87 (3H, m), 1.1-2.9 (54H, m), 4.13-5.00 (9H, m) Example 21 (10 SteD 1 EMI101.2 EMI102.1 Heptanoyl-L-Ala-y-D-Glu(a-OBz1) - (L) -Z- (D) -mesoDAP- (D)-OEt-(L)-D-AlaOEt (3) was prepared substantially in the same manner as Step 1 of Example 4. IR (Nujol) : 3260, 1730, 1680, 1620 cm 1 NMR (CDCl3), #: 0.85 (3H, m), 1.05-2.40 (29H, m), 3.93-4.70 (8H, m), 5.06 (2H, s), 5.11 (2H, s), 5.58 (1H, d, J=8Hz), 6.60 (2H, d, J=8Hz), 7.20 (1H, d, J=8Hz), 7.31 (10H, s) (2) Step 2 EMI102.2 Heptanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(D)-OEt-(L)- D-AlaOEt (4) was prepared, substantially in the same manner as step 2 of Example 20. IR (Nujol) : 3280, 1740, 1635 cm-1 NMR (DMSO-d6), #: 0.87 (3H, m), 1.02-2.33 (27H, m), 3.40 (1H, m) Example 22 (1) Step 1. EMI103.1 1-N-Benzyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl-L-Alay-D-Glu(a-OBzl)-(L)-Z-(D)-mesoDAP-(D)-NHNHZ-(L)-GlyOH (3) was prepared in a similar manner to.Step 1 of the Example 4. mp. 176-1780C IR (Nujol): 3350, 1750, 1670, 1530 cml. NMR (DMSO-d6): 61.0-2.2 (13H, m), 1.85 (3H, s), 1.94 (3H, s), 2.00 (3H, s), 2.10 (3H, s), 3.6-4.5 (8H, m), 4.95 (2H, s), 5.00 (2H, s), 5.06 (2H, s), 5.1-5.7 (2H, m), 7.20 (5H, s), 7.28 (15H, s), , 7.6-8.6 (3H, m). (2) Step 2. EMI104.1 l-N-Benzyl-2,3,4,5-O-tetraacetyl-D-glucaramoyl-L-Ala- &gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(D)-NHNH2-(L)-GlyOH (4) was prepared in a similar manner to the Example 1, Step 2. mp. 178-181 (dec) IR (Nujol): 3300, 1750, 1650, 1530 cm-1. NMR (CH3OD): #1.1-2.5 (13H, m), 1.83 (3H, s), 2.00 (3H, s), 2.13 (3H, s), 2.23 (3H, s), 3.85 (2H, s), 7.25 (5H, s). (3) Step 3. EMI104.2 EMI105.1 l-N-\Benzyl-2t3t4x5-O-tetraacetyl-D-glucaramoyl-L-Ala- &gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH (5) was prepared in a similar manner to the Example 14 Step 3. mp. 145-1500C IR (Nujol): 3350, 1760, 1660 (sh), 1650, 1530 cm 1. NMR (D2O): #1.43 (3H, d, J=7Hz), 1.3-2.5 (10H, m),'2.00 -(3H, s), 2.10 (3H, s), 2.23 (6H, s), 3.7-4.0 (3H, m), 4.0-4.5 (3H, m), 5.1-6.0 (4H, m), 7.37 (5H, s). (4) Step 4 EMI105.2 1-N-Benzyl-D-glucaramoyl-L-Ala-&gamma;-Glu(&alpha;-OH)-(L)- mesoDAP-(L)-GlyOH (6) was prepared in a similar manner to the Example 14 Step 4. mp. 117-1200C IR (Nujol): 3350, 1730, 1640 (sh), 1540 cm-1. NMR (D2O): #1.42 (3H, d, J=7Hz), 1.2-2.5 (10H, m), 3.86 (2H, s), 3.5-5.0 (10H, m), 7.35 (5H, s). Example 23 (1) Step 1 EMI107.1 1-N-Lauryl-2,3,4,5-0-tetraacetyl-D-glucaramoyl-L-Ala y-D-Glu(wOBzl)-(L) - - (D)-mesoDAP-(D)-NHNHZ-(D)-GlyOH (III) was prepared in a similar manner to the Example 4 , step 1. IR (Nujol): 3350, 1760, 1670, 1650, 1540 cm NMR (DMSOD6): 6 0.9 (3H, m), 1.0-2.3 (33H, m), 1.95 (3H, s), 2.00 (3H, s), 2.07 (3H, s), 2.15 (3H, s), 3.00 (2H, m), 3.2-4.6 (10H, m), 5.08 (2H, s) , 5.13 (2H, s) , 5.18 (2H, s), 5.2-5.8 (2H, m), 7.37 (15H, s), 7.7-8.5 (5H, m), 9.20 (1H, m), 9.90 (1H, s). (2) Step 2 EMI108.1 1-N-Lauryl-2,3,4,5-0-tetraacetyl-D-qlucaramoyl-L-Ala &gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(D)-NHNH2-(L)-GlyOH (II) was prepared in a similar manner to the Example 1, step 2. IR(Nujol): 3350, 1760, 1660, 1540 cm 1 NMR (CD3OD): 6 0.90 (3H, m), 1.0-2.4 -(33H, m), 2.02 (6H, s), 2.13 (3H, s), 2.20 (3H, s), 2.9-3.3 (2H, m), 3.80 (2H, s). (3) Step 3 EMI109.1 l-N-Lauryl-2,3,4,5-O-tetraacetyl-D-qlucaramoyl-L-Ala- &gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH (II) was prepared in a similar manner to the Example 14, step 3. IR (Nujol): 3350, 1760, 1660, 1540 cm 1 NMR (D2O): 6 0.80 (3H, m), 1.0-2.5 (33H, m), 2.08 (6H, s), 2.16 (3H, s), 2.20 (3H, s), 3.10 (2H, m) , 3.78 (2H, s). (4) Step 4 EMI110.1 1-N-Lauryl-D-glucaramoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- mesoDAP-(L)-GlyOH (II) was prepared in a similar manner to the Example 4 step 4. IR (Nujol): 3300, 1720, 1640, 1540 cm NMR (D2O): 6 0.80 (3H, m) , 1.0-2.5 (33H, m), 3.20 (2H, m), 3.80 (2H, m). Example 24 ¯¯ (1) Step 1 EMI111.1 Boc-(D)-mesoDAP-(L)-Gly-(D)-NHNHBoc (1) (2.31 g) was dissolved in a mixture of dioxane (60 ml) and water (50 ml) and triethylamine (610 mg) and Z-D Ala-D-Glu(a-OBzl)-y-OSu (1)(2.70 g) were added. The mixture was left for 18 hours at room temperature and concentrated at a reduced pressure. The mixture of water (30 ml), 1N-hydrochloric acid (10 ml) and ethyl acetate (100 ml) were added to the residue. The organic layer was separated and washed with brine, dried over magnesium sulfate, concentrated in vacuo. The resulting amorphous powder was washed with diisopropyl ether and collected to give a crude product, which was purified by silica gel chromatography (100 ml) eluting with chloroform-methanol (10:1-5:1, v/v). The fractions containing the object compound (3) were collected and concentrated to dryness to yield Z-D-Ala-&gamma;-D-Glu-&alpha;-OBzl-(L)-Boc-(D)-mesoDAP- (L)-Gly-(D)-NNNHBoc (3)(1.09 g). mp - 125 C (dec.). - 4.39 (C=0.21, CHCl3) IR (Nujol) : 3300, 1720, 1670 cm 1 (2) Step 2 EMI112.1 Z-D-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP-(L)- Gly-(D)-NHNHBoc (3)(980 ml) was dissolved in acetic acid (20 ml) and hydrogenated under an atomospheric pressure of hydrogen over 10% palladium-charcoal (200 mg). After removal of the catalyst the filtrate was concentrated at a reduced pressure. The resulting syrup was dissolved in water (5 ml) and applied for HP-20 column chromatography (50 ml) eluting with w-ater-methanol (1:1, v/v). The fractions containing the object compound (4) were collected and evaporated to dryness to yield H-D-Ala-&gamma;-D-Glu-(L)-Boc-(D) mesoDAP-(L)-Gly-(D)-SHNHBoc (4)(610 mg). mp - 1590C (dec.), [&alpha;]D -17.30 (C=0.1, meOH). IR (Nujol) : 3270, 1670 cm 1 NMR (CD2OD): 61.1-2.4 (31H, m), 3.70-4.55 (6H, m) Example 25 (1) Step 1 EMI113.1 To a solution of Z-(D)-meso-DAP-(L)-D-AlaOH (2) (918 mg) in the mixture of methylene chloride (t5 ml) and methanol C6 ml) was added triethylamine (760 mg). After the solution turned clear, palmitoyl-L-Ala-D Glu(OSu)OBzl (1)(1.61 g) was added to the solution. The mixture was kept for 18 hours at the room temperature and concentrated in vacuo. To the residue were added water (30 ml) and lN-hydrochloric acid (8 ml). The precipitate was collected, washed with water and dried to give a crude product (2.06.g), which was washed with hot diisopropylether to give palmitoyl-L-Ala-&gamma;-D-Glu-(&alpha;-OBzl)-(L)-Z-(D)-mesoDAP- (L)-D-AlaOH (3)(2.00 g). mp 185-1870C. [&alpha;]D-15.38 (C=0.21,AcOH) IR (Nujol) : 3300, 1725, 1690, 1630 cm 1 NMR (CDCl3-CD3OD) :d 0.87 (3H, m), 1.0-2.4 (44H, m), 4.1-4.6 (5H, m), 5.06 (2H, s) (2) Step 2 EMI114.1 Palmitoyl-L-Ala-&gamma;-D-Glu-(&alpha;-O-Bzl)-(L)-Z-(D)- mesoDAP-(L)-D-Ala-OH (3) (1.86 g) was dissolved in acetic acid (40 ml) and hydrogenated under an atmospheric pressure of hydrogen over 10% palladium-charcoal (1.0 g). After removal of the catalyst, acetic acid was evaporated off in vacuo. To the residue was added diisopropylether and the crystalline mass was collected to give palmitoyl-L-Ala-y-D-Glu-(L)mesoDAP-(L)-D-AlaOH (4)(1.30 g). mp. 185-190 C.- [&alpha;]D-14.07 (C=0.21, AcOH) IR (Nujol) : 3320, 1730(sh), 1710, 1625 cm-1 NMR (NaOD-D2O, #) : 0.87 (3H, m), 1.05-2.60 (44H, m), 3.91-4.54 (5H, m) Example 26 (1) Step 1 EMI115.1 To the solution of H-L-Ala-y-D-Glu-( -OH)-(L)- Boc-(D)-meso-DAP-(L)-D-Ala-OH (1)(528 mg) in a mixture of methylene chloride (20 ml) and methanol (6 ml) were added triethylamine (314 mg) and triacontanoic acid-N-hydroxysuccinimide ester (518 mg). After stirring for 16 hours at room temperature, the reaction mixture was concentrated in vacuo and the mixture of water (10 ml).and lN-hydrochloric acid (4 ml) was added to the residue. The precipitates were collected, washed with water and dried to give a crude product, which was washed with hot diisopropylether to give triacontanoyl-L-Ala-&gamma;-D-Glu-(&alpha;-OH)- (L)-Boc-(D)-mesoDAP-(L)-D-AlaOH (2) (610 mg). mp - 157 C (dec.). [&alpha;]d-14.67 (C=0.20, AcOH). IR (Nujol) : 3280, 1720, 1625 cm NMR (CDCl3-CD3OD, 6): 0.92 (3H, m), 1.1-2.1 (77H, m), 2.15-2.50 (4H, m). (2) Step 2 EMI116.1 To the suspension of triacontanoyl-L-Ala-y-D Glu-(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)-D-Ala-OH (2)(500 mg) in acetic acid (20 ml) was added acetic acid saturated with hydrogen chloride (10 ml) and the mixture was stirred on a steam bath for 5 minutes and cooled to room temperature and kept for 1.5 hours at the same temperature. The reaction mixture was concentrated in vacuo and the residue was washed with water and the precipitates were collected and dried to give triacontanoyl-L-Ala-&gamma;-D-Glu-(&alpha;-OH)-(L)-meso- DAP-(L)-D-AlaOH (412 mg). mp - 185 C (dec.). - -l IR (Nujol) : 3300, 1720, 1625 cm NSiR (CF3CO2H,8) : 0.90 (3H, m). Example 27 (1) Step 1 EMI117.1 n-Heptanoyl-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Z-(D)-mesoDAP-(L)- D-AlaOEt-(D)OEt(3) was prepared substantially in the same manner as step 1 of Example 25. mp 141-142 C. [&alpha;]D=-10.31 (C=0.22, CHCl3) NMR (DMSO-d6), 6: 0.85 (3H, m), 1.05-2.40 C29H, m), 3.93-4.70 (8H, m) , 5.06 (2H, s) , 5.11 (2H, s) 5.58 (1H, d, J=8Hz), 6.60 (2H, d, J=8Hz), 7.20 (1H, d, J=8Hz), 7.31 (10H, s) EMI118.1 n-Heptanoyl-y-D-Gluta-OH)-(L)-mesoDAP-(L)-D-AlaOEt. (D)-OEt (4) was prepared substantially in the same manner as step 2 of Example 25, mp. 179-1820C. [&alpha;]D=-13.85 (C=0.29, AcOH) NMR (DMSO-d6), : 0.87 (3H, m), 1.02-2.33 (27H, m), 3.40 (1H, m). Example 28 (1) Step 1 EMI118.2 Heptanoyl-&gamma;-D-Glu-(&alpha;-OBzl)-(L)-2-(D)-mesoDAP-(D)- OBt-(L)-D-AlaOH (3) was prepared substantially in the same manner as step 1 of Example 25, mp. 94-102 C. [&alpha;]D -1.06 (C=0.21, CHCl3) IR (Nujol) : 3280, 1735, 1685, 1630 cm NMR (CDCl3, 6) : 0.86 (3H, m), 1.05-2.55 (26H, m), 3.9-4.9 (6H, m), 5.10 (2H, s), 5.16 (2H, s), 7.32 (10H, s). (2) Step 2 EMI119.1 Heptanoyl-y-D-Glu-(a-OBzl)-(L)-Z-(D)-mesoDAP-(D)-OEt- (L)-D-AlaOH (3) (930 mg) was dissolved in acetic acid (20 ml) and hydrogenated under an atmospheric pressure of hydrogen over 10% palladium-charcoal (200 mg). After removal of the catalyst, acetic acid was evaporated in vacuo. The residue was purified by column chromatography of HP-20 (50 ml) with ethanol-H20 (3:7, v/v) as an eluent to give heptanoyl-y-D-Glu-( -OH)-(L)- mesoDAP-(D)-OBt-(L)-D-AlaOH (4)(490 mg). mp. 218 C [&alpha;]D-14.63 (C=0.2, H2O) IR (.Nujol) : 3280, 1740, 1635 cm NMR (D2O, 6) : 0.90 (3H, m), 1.2-2.6 (26H, m), 4.1-4.55 (6H, m).

Claims: We claim 1. A compound of the formula or its pharmaceutically acceptable salt EMI120.1 wherein R1 is nroctanoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is n-octanoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is benzyl, R3 is 1-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen, and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is benzyl, R3 is methoxy, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is stearoyl, n is an integer of O, R2 is benzyl, R3 is methoxy, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is stearoyl, n is an integer of 0, R2 is hydrogen, R3 is methoxy, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is n-docosanoyl, n is an integer of 1, R2 is benzyl, R3 is 1-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is n-docosanoyl, n is an integer of l, R2 is benzyl, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is n-docosanoyl, n is an integer of 1, R2 is hydrogen, R3 is 1-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is n-docosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is n-tetracosanoyl, n is an integer of 1, R2- is benzyl, R3 is l-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is n-tetracosanoyl, n is an integer of 1, R2 is benzyl, R3 is l-methoxycarbonylethylamino-, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or. R1 is n-tetracosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is benzyl, R3 is methoxycarbonylmethylamino, R4 is methoxycarbonyl, and R5is t-butoxycarbonyl; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is benzyl, R3 is methoxycarbonylmethylamino, R4 is methoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is hydrogen, R3 is methoxycarbonylemthylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5is t-butoxycarbonyl; or R1. is heptanoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is heptanoyl, n is an integer of O, R2 is methyl, R3 is l-methoxycarbonylethylamino, R is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is heptanoyl, n is an integer of O, R2 is methyl, R3 is l-methoxycarbonylethylamino, d methoxycarbonyl and R5 is hydrogen; or R1 is octanoyl, n is an integer of O, R2 is methyl, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is benzyl, R3 is methoxycarbonylmethylamino, R4 is carboxy, and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is hydrogen, R3 is methoxycarbonylmethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 1-N-n-hexyl-2,3,4,5-0-tetraacetyl-D glucaramoyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is 3-benzyloxycarbonylcarbazoyl and R5 is benzyloxycarbonyl; or R1 is l-N-n-hexyl-2,3,4,5-0-tetraacetyl-D- glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carbazoyl and R5 is hydrogen; or R1 is 1-N-n-hexyl-2,3,4,5-O-tetraacetyl-D glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is l-N-n-hexyl-D-glucaramoyg n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is methoxycarboylmethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 2,3; 4,6-diisopropylidene-L-2-ketogulonoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, 5 R4 is hydrogen and R5 is hydrogen; or R1 is 2-keto-L-gulonoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is 2-keto-L-gulonoyl, n is an integer of O, R2 is hydrogen, R3 is 1-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is 2,3; 4,6-diisopropylidene-2-keto-L-gulonoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is 2-keto-L-gulonoyl, n is an integer of 0, R2 is benzyl,R3 is l-carboxyethylamino, is is carboxy and R5 is hydrogen; or R1 is 2-keto-L-gulonoyl, n is an integer of O, R2 is hydrogen, R3 is 1-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is stearoyl, n is an integer of 1, R2 is benzyl, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is stearoyl, n is an integer of 1, R2 is hydrogen, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is hydrogen; or is is heptanoyl, n is an integer of 1, R2 is benzyl, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and RS is benzyloxycarbonyl; or R1 is heptanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is hydrogen; or R1 is 1-N-benzyl-2,3,4,5-0-tetraacetyl-D glucaramoyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is 3-benzyloxycarbonylcarbazoyl and R5 is benzyloxycarbonyl; or R1 is 1-N-benzyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3is carboxymethylamino, R4 is carbazoyl and R5 is hydrogen; or R1 is 1-N-benzyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is l-N-benzyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 1-N-lauryl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n -is an integer of 1, 3 R2 is benzyl, R3 is carboxymethylamino, R4 is 3-benzyloxycarbonylcarbazoyl and S R is benzyloxycarbonyl; or * is l-N-lauryl-2,3,4-5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R@ is carboxymethylamino, S R4 is carbazoyl and R is hydrogen; or R1 is 1-N-lauryl-2,3,4,5-O-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is l-N-lauryl-D-glucaramoyl, n is an integer of 1, R2is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is palmitoyl, n is an integer of 1, R2 is benzyl, R3 is l-carboxyethylamino, R4 is carboxy and R5 is benzyloxycarbonyl; or R1 is palmitoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is triacontanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is triacontanoyl, n is an integer of 1, R2 is hydrogen, R3 is 1-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is heptanoyl, n is an integer of O, R2 is benzyl, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is heptanoyl, n is an integer of O, R2 is hydrogen, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is hydrogen; or R1 is heptanoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is ethoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is heptanoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is ethoxycarbonyl and R5 is hydrogen. 2. A compound according to claim 1, wherein R1 is n-octanoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is hydrogen, R3 is methoxy, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is n-docosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-methoxycarbonylethylamino, 5 R4 is methoxycarbonyl and R is hydrogen; or R1 is n-docosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is n-tetracosanoyl, n is an integer of 1, p2 is hydrogen, R3 is l-methoxycarbonylethylamino, is methoxycarbonyl and R5 is hydrogen; or R1 is heptanoyl, n is an integer of O, R2 is methyl, R3 is 1-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is hydrogen, R3 is methoxycarbonylmethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is l-N-hexyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or is is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is methoxycarbonylmethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, 4 5 R is methoxycarbonyl and R is hydrogen; or R is 2-keto-L-gulonoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is 2-keto-L-gulonoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, is is carboxy and R5 is hydrogen; or is is stearoyl, n is an integer of 1, R2 is hydrogen, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is hydrogen; or R1 is heptanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is hydrogen; or R1 is l-N-benzyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is l-N-lauryl-D-glucaramoyl, N is an integer of 1, R is hydrogen, R3 is carboxymethylamino,- R4 is carboxy and R5 is hydrogen; or R1 is palmitoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is triacontanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1,is heptanoyl, n is an integer of O, R2 is hydrogen, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is hydrogen; or R1 is heptanoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is ethoxycarbonyl and R5 is hydrogen. 3. A compound according to claim 1, where in R1 is n-octanoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is hydrogen, R3 is methoxy, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is n-docosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is stearoyl, n is an integer of 1, R2 is hydrogen, R3 is 1-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is hydrogen; or R1 is palmitoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen. 4. A process for preparation of a compound of the formula or its pharmaceutically acceptable salt EMI131.1 wherein R1 is n-octanoyl, n is an integer of O, R2 is benzyl, R3 is l--carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is n-octanoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or Rl is stearoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, 5 R4 is hydrogen and R is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen, and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is benzyl, R3 is methoxy, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is stearoyl, n is an integer of O, R2 is benzyl, R3 is methoxy, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is hydrogen, R3 is methoxy, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is n-docosanoyl, n is an integer of 1, R2 is benzyl, R3 is 1-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is n-docosanoyl, n is an integer of 1, R2 is benzyl, R3 is 1-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is n-docosanoyl, n is an integer of 1, R2 is hydrogen, R3 is 1-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is n-docosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is n-tetracosanoyl, n is an integer of 1, R2 is benzyl, R3 is l-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is n-tetracosanoyl, n is an integer off 1, R2 is benzyl, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or is is n-tetracosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is n-tetracosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, 4 5 R, is carboxy and R is hydrogen; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is benzyl-, R3 is methoxycarbonylmethylamino, R4 is is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is benzyl, R3is methoxycarbonylmethylamino, R4 is methoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is hydrogen, R3 is methoxycarbonylmethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is 2-acetoxypropionyl-, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is heptanoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is heptanoyl, n is an integer of O, R2 is methyl, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is heptanoyl, n is an integer of O, R2 is methyl, R3 is 1-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is octanoyl, n is an integer of O, R2 is methyl, R3 is 1-methoxycarbonylethylamino, R is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is octanoyl, n is an integer of O, R2 is methyl, R3 is 1-methoxycarbonylethylamino, R4 is methoxy carbonyl and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is benzyl, R3 is methoxycarbonylmethylamino, R4 is carboxy, and R5 is t-butoxycarbonyl; or R; is 2-hydroxypropionyl, n is an integer of 1, R2 is hydrogen, R3 is methoxycarbonylmethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 1-N-n-hexyl-2,3,4,5-O-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is benzyl, R is carboxy methylamino, R4 is 3-benzyloxycarbonylcarbazoyl and R5 is benzyloxycarbonyl; or R1 is 1-N-n-hexyl-2,3,4,5-O-tetraacetyl-D- glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carbazoyl and S R is hydrogen; or R1 is 1-N-n-hexyl-2,3,4,5-O-tetraacetyl-D- glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 1-N-n-hexyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, 4 R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxyemthylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is methoxycarbonylmethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, 5 R4 is methoxycarbonyl and R is hydrogen; or R1 is 2,3; 4,-6-diisopropylidene-L-2-ketogulonoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1,is 2-keto-L-gulonoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is 2-keto-L-gulonoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is 2,3; 4,6-diisopropylidene-2-keto-L-gulonoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is 2-keto-L-gulonoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or Rl is 2-keto-L-gulonoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino R4 is carboxy and R5 is hydrogen; or R1 is stearoyl, n is an integer of 1, R2 is benzyl, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is stearoyl, n is an integer of 1, R2 is hydrogen, R3 is 1-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is hydrogen; or R1 is heptanoyl, n is an integer of 1, R2 is benzyl, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is heptanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-ethoxycarbonylethylamino, 5 R4 is ethoxycarbonyl and R is hydrogen; or R1 is 1-N-benzyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is 3-benzyloxycarbonyl carbazoyl and 5 R is benzyloxycarbonyl; or R1 is 1-N-benzyl-2,3,4,5-O.-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carbazoyl and R5 is hydrogen; or R1 is 1-N-benzyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and is hydrogen; or R1 is l-N-benzyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 1-N-lauryl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is benzyl, is is carboxymethylamino, R4 is 3-benzyloxycarbonylcarbazoyl and R5 is benzyloxycarbonyl; or R1 is 1-N-lauryl-2,3,4,5-0-tetraacctyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carbazoyl and R5 is hydrogen; or R1 is 1-N-lauryl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, is carboxymethylamino, R4 is carboxy and is is hydrogen; or R1 is 1-N-lauryl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is palmitoyl, n is an integer of 1, R2 is benzyl, R3 is l-carboxyethylamino, R4 is carboxy and R5 is benzyloxycarbonyl; or R1 is palmitoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is triacontanoyl, n is an integer of 1, R2 is hydrogen, R3 is 1-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is triacontanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is heptanoyl, n is an integer of O, R2 is benzyl, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is heptanoyl, n is an integer of O, R2 is hydrogen, R3 is 1-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is hydrogen; or R1 is heptanoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, 5 R4 is ethoxycarbonyl and R is benzyloxycarbonyl; or R1 is heptanoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is ethoxycarbonyl and R5 is hydrogen, which comprises, reacting a compound of the formula or its salt EMI139.1 with a compound of the formula or its salt EMI140.1 to give a compound of the formula or its salt EMI140.2 or reacting of a compound of the formula or its salt EMI140.3 with a compound of the formula or its salt EMI140.4 to give a compound of the formula or its salt EMI141.1 or reacting a compound of the formula or its salt EMI141.2 with a compound of the formula or its salt :t EMI141.3 to give a compound of the formula or its salt..: EMI141.4 or reacting a compound of the formula or its salts EMI142.1 with a compound of the formula or its salt EMI142.2 to give a compound of the formula or its salt EMI142.3 or reacting a compound of the formula or its salt EMI142.4 with a compound of the formula or its salt EMI142.5 to give a compound of the formula or its salt EMI143.1 or reacting a compound of the formula or its salt EMI143.2 with a compound of the formula or its salt EMI143.3 to ìve a compound of the formula or its salt EMI143.4 or reacting a compound of the formula or its salt EMI143.5 with a compound of the formula or its salt EMI144.1 to give a compound of the formula or its salt EMI144.2 reacting a compound of the formula or its salt EMI144.3 with a compound of the formula or its salt EMI144.4 to give a compound of the formula or its salt EMI144.5 or reacting a compound of the formula or its salt EMI145.1 with a compound of the formula or its salt EMI145.2 to give a compound of the formula or its salt EMI145.3 or reacting a compound of the formula or its salt EMI145.4 with a compound of the formula or its salt EMI145.5 to give a compound of the formula or its salt EMI146.1 or reacting a compound of the formula or its salt EMI146.2 with a compound of the formula or its salt EMI146.3 to give a compound of the formula or its salt EMI146.4 or reacting a compound of the'formula or its salt EMI147.1 with a compound of the formula or its salt EMI147.2 to give a compound of the formula or its salt EMI147.3 or reacting a compound of the formula or its salt EMI147.4 with a compound of the formula or its salt EMI148.1 to give a compound of the formula or its salt EMI148.2 or reacting a compound of the formula or its salt EMI148.3 with a compound of the formula or its salt EMI148.4 to give a compound of the formula or its salt EMI149.1 or reacting a compound of the formula or its salt EMI149.2 with a compound of the formula or its salt EMI149.3 to give a compound of the formula or its salt EMI149.4 or reacting a compound of the formula or its salt EMI150.1 with a compound of the formula or its salt EMI150.2 to give a compound of the formula or its salt EMI150.3 or reacting a compound of the formula or its salt EMI150.4 with a compound of the formula or its salt EMI150.5 to give a compound of the formula or its salt EMI151.1 or reacting a compound of the formula or its salt EMI151.2 with a compound of the formula or its salt EMI151.3 to give a compound of the formula or its salt EMI151.4 or reacting a compound of the. formula or its salt EMI151.5 with 1-N-n-hexyl-2,3,4,5-0-tetraacetyl-D-glucaramic acid, 1-N-benzyl-2,3,4,5-0-tetraacetyl-D-glucaramic acid, l-N-lauryl-2,3,4,5-O-tetraacetyi-D-glucaramic acid or their reacting derivatives to give a compound of the formula or its salt EMI152.1 wherein Ra is l-N-n-hexyl-2,3,4,5-O-tetraacetyl-Dglucaramoyl, 1-N-benzyl-2,3,4,5-0-tetraacetyl-Dglucaramoyl or 1-N-lauryl-2,3,4,5-0-tetraacetyl-Dglucaramoyl, or reacting a compound of the formula or its salt EMI152.2 with triacontanoic acid or its reactive derivative to give a compound of the formula or its salt EMI152.3 or reacting a compound of the formula or its salt EMI153.1 with a methylating agent to give a compound of the formula or its salt EMI153.2 or reacting a compound of the formula or its salt EMI153.3 with a methylating agent to give a compound of the formula or its salt EMI153.4 wherein Rb is n-docosanoyl or n-tetracosanoyl, or reacting a compound of the formula or its salt EMI154.1 with a methylating agent to give a compound of the formula or its salt EMI154.2 or reacting a compound of the formula or its salt EMI154.3 with a methylating agent to give a compound of the formula or its salt EMI154.4 reacting a compound of the formula or its salt EMI155.1 with a compound of the formula or its salt EMI155.2 and subjecting the resulting compound to elimination reaction of the protective group to give a compound of the formula or its salt EMI155.3 or subjecting a compound of the formula or its salt EMI155.4 wherein R1 is n-octanoyl, n is an integer of O, R2 is benzyl, R3 is l-cÅarboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is benzyl, R3 is 1-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is stearoyl, n is an integer of O,. R2 is benzyl, R3 is methoxy, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is stearoyl, n is an integer of 0, R2 is benzyl, R3 is methoxy, R4 is methoxycarbonyl and R5 is hydrogen; or is is n-docosanoyl, n is an integer of 1, R2 is benzyl, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and RS is t-butoxycarbonyl; or is is n-docosanoyl, n is an integer of 1, R2 is benzyl, R3 is 1-carboxyethylamino, is is carboxy and R5 is t-butoxycarbonyl; R1 is n-.tetracosanoyl, n is an integer of I, R2 is benzyl, R3 is 1-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is n-tetracosanoyl, n is an integer of 1, R2 is hydrogen, R3 is 1-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is benzyl, R3 is methoxycarbonylmethylamino, R4 is methoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is heptanoyl, n is an integer of O, R2 is methyl, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is octanoyl, n is an integer of O, R2 is methyl, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is benzyl, R3 is methoxycarbonylmethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, is is methoxycarbonyl and R5 is t-butoxycarbonyl; or R1 is 1-N-n-hexyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an interger of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is 3-benzyloxycarbonyl carbazoyl and R5 is benzyloxycarbonyl; or R1 is 1-N-n-hexyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, is is carboxymethylamino, R4 is carbazoyl and R5 is hydrogen; or R1 is 1-N-n-hexyl-2,3,4,5-O-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, is is carboxymethylamino, R4 is carboxy and is is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and R is t-butoxycarbonyl; or R1 is 2,3; 4,6-diisopropylidene-L-2-ketogulonoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is hydrogen and is is hydrogen; or A R1 is 2-keto-L-gulonoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is 2,3; 4,6-diisopropylidene-Z-keto-L-gulonoyl, n is an integer of O, R2 is benzyl, R3 is 1-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; or R1 is 2-keto-L-gulonoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is stearoyl, n is an integer of 1, R2 is benzyl, R3 is 1-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is heptanoyl, n is an integer of 1, R2 is benzyl, R3 is 1-ethoxycarbonylethylamino, 5 R4 is ethoxycarbonyl and R is benzyloxycarbonyl; or R1 is 1-N-benzyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is 3-benzyloxycarbonyl carbazoyl and R5 is benzyloxycarbonyl; or R1 is 1-N-benyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carbazoyl and R5 is hydrogen; or R1 is 1-N-benzyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 1-N-lauryl-2,3,4ç5-O-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is benzyl, R3 is carboxymethylamino, R4 is 3-benzyloxycarbonyl carbazoyl and R5 is benzyloxycarbonyl; or R1 is 1-N-lauryl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carbazoyl and R5 is hydrogen; or R1 is 1-N-lauryl-2,3,4 ,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is palmitoyl, n is an integer of 1, R2 is benzyl, R3 is l-carboxyethylamino, 4 R4 is carboxy and R5 is benzyloxycarbonyl; or R1 is triacontanoyl, n is an integer of l R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is t-butoxycarbonyl; R1 is heptanoyl, n is an integer of O, R2 is benzyl, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is benzyloxycarbonyl; or R1 is heptanoyl, n is an integer of O, R2 is benzyl, R3 is l-carboxyethylamino, R4 is ethoxycarbonyl and R5 is benzyloxycarbonyl, to a elemination reaction of protective group(s) to give a compound of the formula or its salt EMI160.1 wherein R1 is n-octanoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is hydrogen, R3 is 1-carboxyethylamino, is hydrogen and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is benzyl, R3 is methoxy, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is stearoyl, n is an integer of O, R2 is hydrogen, R3 is methoxy, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is n-docosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is n-docosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is n-tetracosanoyl, n is an integer of 1 R2 is hydrogen, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is n-tetracosanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-acetoxypropionyl, n is an integer of 1, R2 is hydrogen, R3 is methoxycarbonylmethylamino, S R4 is methoxycarbonyl and R is hydrogen; or R1 is heptanoyl, n is an integer of O, R2 is methyl, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or is is octanoyl, n. is-an integer of O, R2 is methyl, R3 is l-methoxycarbonylethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is hydrogen, R3 is methoxycarbonylmethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 1-N-n-hexyl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and is is hydrogen; or R1 is l-N-n-hexyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 2-hydroxypropionyl, n is an integer of 1, R2 is methyl, R3 is carboxymethylamino, R4 is methoxycarbonyl and R5 is hydrogen; or R1 is 2-keto-L-gulonoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is hydrogen and R5 is hydrogen; or R1 is 2-keto-L-gulonoyl, n is an integer of O, R2 is hydrogen, R3 is 1-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is stearoyl, n is an integer of 1, R2 is hydrogen, R3 is l-ethoxycarbonylethylamino, is ethoxycarbonyl and R5 is hydrogen; or R1 is heptanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is hydrogen; or R1 is 1-N-benzyl-2,3,4,5-O-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is l-N-benzyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is 1-N-lauryl-2,3,4,5-0-tetraacetyl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R1 is l-N-lauryl-D-glucaramoyl, n is an integer of 1, R2 is hydrogen, R3 is carboxymethylamino, R4 is carboxy and R5 is hydrogen; or R4 is carboxy and R is hydrogen; or R1 is palmitoyl, n is an integer of 1, R2 is hydrogen, R3 is 1-carboxyethylamino, R4 is carboxy and R5 is hydrogen; or R1 is triacontanoyl, n is an integer of 1, R2 is hydrogen, R3 is l-carboxyethylamino, is is carboxy and R5 is hydrogen; or R1 is heptanoyl, n is an integer of O, R2 is hydrogen, R3 is 1-ethoxycarbonylethylamino, R4 is ethoxycarbonyl and R5 is hydrogen; or R1 is heptanoyl, n is an integer of O, R2 is hydrogen, R3 is l-carboxyethylamino, R4 is ethoxycarbonyl and R5 is hydrogen. 5. A pharmaceutical composition comprising a compound of claim 1 in association with a pharmaceutically acceptable, substantially nontoxic carrier or excipient.

Inventors: AOKI, HATSUO, ARATANI, MATSUHIKO, HASHIMOTO, MASASHI, HEMMI, KEIJI, IGUCHI, EIKO, IMANAKA, HIROSHI, KITAURA, YOSHIHIKO, KOHSAKA, MASANOBU, KURODA, YOSHIO, NAKAGUCHI, OSAMU, OKADA, SATOSHI, TAKENO, HIDEKAZU, TANAKA, HIROKAZU
Applicants: FUJISAWA PHARMACEUTICAL CO., LTD.
Application year: 1981
Main classification: C07C103
IPC codes: C07K5, A61K38, C07K9